Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________.

Commission File Number: 000-30141

LIVEPERSON, INC.

(Exact name of registrant as specified in its charter)


Delaware						13-3861628
(State or other jurisdiction of incorporation or organization)						(IRS Employer Identification No.)

530 7th Ave, Floor M1
New York, New York						10018
(Address of principal executive offices)						(Zip Code)

(212) 609-4200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

LPSN

The Nasdaq Stock Market LLC

Rights to Purchase Series A Junior
Participating Preferred Stock

None

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

☐

Accelerated Filer

☒

Non-accelerated Filer

☐

Smaller Reporting Company

☐

Emerging Growth Company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

On May 6, 2024, 88,614,097 shares of the registrant’s common stock were outstanding.

LIVEPERSON, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024

INDEX


		Page
	PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited):	4
	Condensed Consolidated Balance Sheets as of March 3 1 , 202 4 and December 31, 202 3	4
	Condensed Consolidated Statements of Operations for the Three Months Ended March 3 1 , 202 4 and 202 3	5
	Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023	6
	Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2024 and 2023	7
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 202 3	8
	Notes to Condensed Consolidated Financial Statements	10
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	33
Item 3.	Quantitative and Qualitative Disclosures A bout Market Risk	39
Item 4.	Controls and Procedures	40
	PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	40
Item 1A.	Risk Factors	40
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	41
Item 3.	Defaults Upon Senior Securities	41
Item 4.	Mine Safety Disclosures	41
Item 5.	Other Information	41
Item 6.	Exhibits	43
	Signatures	45

FORWARD-LOOKING STATEMENTS

Statements in this Quarterly Report on Form 10-Q about LivePerson, Inc. (“LivePerson”, the “Company,” “we,” “our” or “us”) that are not historical facts are forward-looking statements. These forward-looking statements are based on our current expectations, assumptions, estimates and projections about LivePerson and our industry. Our expectations, assumptions, estimates and projections are expressed in good faith, and we believe there is a reasonable basis for them, but we cannot assure you that our expectations, assumptions, estimates and projections will be realized. Examples of forward-looking statements include, but are not limited to, statements regarding future business, future results of operations or financial condition (including based on examinations of historical operating trends) and management strategies. Many of these statements are found in the “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of this Quarterly Report on Form 10-Q. When used in this Quarterly Report on Form 10-Q, the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “projects” and variations of such words or similar expressions are intended to identify forward-looking statements. However, not all forward-looking statements contain these words. Forward-looking statements are subject to risks and uncertainties that could cause actual future events or results to differ materially from those expressed or implied in the forward-looking statements. Important factors that could cause our actual results to differ materially from the forward-looking statements we make in this Quarterly Report on Form 10-Q include those set forth in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 4, 2024 (as amended on April 29, 2024) in the section entitled Part I, Item 1A. “Risk Factors” and in this Quarterly Report on Form 10-Q in the section entitled Part II, Item 1A, “Risk Factors.” It is routine for our internal projections and expectations to change as the year or each quarter in the year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which we base our expectations may change prior to the end of each quarter or the year. Although these expectations may change, we are under no obligation to inform you if they do. Our policy is generally to provide our expectations only once per quarter, and not to update that information until the next quarter. We do not undertake any obligation to revise forward-looking statements to reflect future events or circumstances. All forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Part I — FINANCIAL INFORMATION

Item 1. Financial Statements

LIVEPERSON, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)


	March 31, 2024		December 31, 2023

	(In thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	127,057	$	210,782
Restricted cash	1,960		2,143
Accounts receivable, net of allowance for credit losses of $9,235 and $9,290 as of March 31, 2024 and December 31, 2023, respectively	71,365		81,802
Prepaid expenses and other current assets (Note 1)	20,954		26,981

Total current assets	221,336		321,708
Operating lease right-of-use assets (Note 9)	3,431		4,135
Property and equipment, net (Note 6)	117,893		119,325
Contract acquisition costs, net	39,326		37,354
Intangible assets, net (Note 5)	56,009		61,625
Goodwill (Note 5)	280,956		285,631
Deferred tax assets	4,473		4,527
Other assets	1,264		1,208
Total assets	$	724,688	$	835,513
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	14,528	$	13,555
Accrued expenses and other current liabilities (Note 7)	75,506		97,024
Deferred revenue (Note 2)	92,414		81,858
Convertible senior notes (Note 8)	—		72,393
Operating lease liabilities (Note 9)	2,632		2,719

Total current liabilities	185,080		267,549

Convertible senior notes, net of current portion (Note 8)	512,076		511,565
Operating lease liabilities, net of current portion (Note 9)	1,466		2,173
Deferred tax liabilities	3,002		2,930
Other liabilities	3,881		3,158
Total liabilities	705,505		787,375
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value - 5,000,000 shares authorized, none issued	—		—
Common stock, $0.001 par value - 200,000,000 shares authorized, 91,131,823 and 90,603,519 shares issued, 88,365,750 and 87,837,446 shares outstanding as of March 31, 2024 and December 31, 2023, respectively.	92		91
Treasury stock - 2,766,073 shares at March 31, 2024 and December 31, 2023	(3)		(3)
Additional paid-in capital	921,895		913,522
Accumulated deficit	(892,619)		(856,988)
Accumulated other comprehensive loss	(10,182)		(8,484)
Total stockholders’ equity	19,183		48,138
Total liabilities and stockholders’ equity	$	724,688	$	835,513

See accompanying notes to condensed consolidated financial statements.

LIVEPERSON, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)


	Three Months Ended
	March 31,
	2024		2023

	(In thousands, except share and per share amounts)
Revenue	$	85,149	$	107,661
Costs, expenses and other:
Cost of revenue	29,463		43,096
Sales and marketing	30,130		34,470
General and administrative	21,752		31,447
Product development	30,120		36,519
Impairment of goodwill	3,627		—
Impairment of intangibles and other assets	2,221		—
Restructuring costs	3,309		11,515
Gain on divestiture	—		(17,591)
Amortization of purchased intangible assets	891		874
Total costs, expenses and other	121,513		140,330
Loss from operations	(36,364)		(32,669)
Other income (expense), net:
Interest income, net	1,332		1,801
Other (expense) income, net	(237)		14,662
Total other income, net	1,095		16,463
Loss before provision for income taxes	(35,269)		(16,206)
Provision for income taxes	362		1,214
Net loss	$	(35,631)	$	(17,420)

Net loss per share of common stock:
Basic	$	(0.40)	$	(0.23)
Diluted	$	(0.40)	$	(0.23)
Weighted-average shares used to compute net loss per share:
Basic	88,081,654		75,774,812
Diluted	88,081,654		75,774,812

See accompanying notes to condensed consolidated financial statements.

LIVEPERSON, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)


	Three Months Ended
	March 31,
	2024		2023

	(In thousands)
Net loss	$	(35,631)	$	(17,420)
Foreign currency translation adjustment	(1,698)		866
Total comprehensive loss	$	(37,329)	$	(16,554)

See accompanying notes to condensed consolidated financial statements.

LIVEPERSON, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)


	Common Stock			Treasury Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Equity
	Shares	Amount		Shares	Amount

	(In thousands, except share data)
Balance at December 31, 2023	90,603,519	$	91	(2,766,073)	$	(3)	$	913,522	$	(856,988)	$	(8,484)	$	48,138

Common stock issued upon vesting of restricted stock units	432,701	1		—	—		1		—		—		2
Stock-based compensation	—	—		—	—		8,251		—		—		8,251

Common stock issued under Employee Stock Purchase Plan (ESPP)	95,603	—		—	—		121		—		—		121



Net loss	—	—		—	—		—		(35,631)		—		(35,631)
Other comprehensive loss	—	—		—	—		—		—		(1,698)		(1,698)
Balance at March 31, 2024	91,131,823	$	92	(2,766,073)	$	(3)	$	921,895	$	(892,619)	$	(10,182)	$	19,183


	Common Stock			Treasury Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Equity
	Shares	Amount		Shares	Amount

	(In thousands, except share data)
Balance at December 31, 2022	78,350,984	$	78	(2,766,073)	$	(3)	$	771,052	$	(692,362)	$	(10,677)	$	68,088

Common stock issued upon exercise of stock options	18,687	—		—	—		130		—		—		130
Common stock issued upon vesting of restricted stock units	413,252	1		—	—		—		—		—		1
Stock-based compensation	—	—		—	—		9,560		—		—		9,560

Common stock issued under ESPP	87,794	—		—	—		724		—		—		724
Issuance of common stock in connection with acquisitions	—	—		—	—		380		—		—		380
Activity related to divestiture	—	—		—	—		66,775		(64,100)		57		2,732
Net loss	—	—		—	—		—		(17,420)		—		(17,420)
Other comprehensive income	—	—		—	—		—		—		809		809
Balance at March 31, 2023	78,870,717	$	79	(2,766,073)	$	(3)	$	848,621	$	(773,882)	$	(9,811)	$	65,004

See accompanying notes to condensed consolidated financial statements.

LIVEPERSON, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Three Months Ended March 31,
	2024		2023

	(In thousands)
OPERATING ACTIVITIES:
Net loss	$	(35,631)	$	(17,420)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	7,558		11,332
Depreciation	8,225		7,362
Reduction of operating lease right-of-use assets	653		658
Amortization of purchased intangible assets and finance leases	4,217		5,435
Amortization of debt issuance costs	610		920


Impairment of goodwill	3,627		—
Impairment of intangible and other assets	2,221		—
Change in fair value of contingent consideration	—		(1,709)
Gain on repurchase of convertible notes	—		(6,100)
Allowance for credit losses	4,722		1,079
Gain on divestiture	—		(17,591)
Deferred income taxes	75		589
Equity loss in joint venture	—		618
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	5,422		(34,731)
Prepaid expenses and other current assets	5,854		(6,262)
Contract acquisition costs	(2,370)		530
Other assets	(75)		79
Accounts payable	1,966		(9,910)
Accrued expenses and other current liabilities	(16,976)		41,266
Deferred revenue	10,852		24,750
Operating lease liabilities	(738)		(944)
Other liabilities	887		(5,869)
Net cash provided by (used in) operating activities	1,099		(5,918)
INVESTING ACTIVITIES:
Purchases of property and equipment, including capitalized software	(11,501)		(9,625)

Purchases of intangible assets	(1,209)		(1,355)
Proceeds from divestiture	—		13,819

Net cash (used in) provided by investing activities	(12,710)		2,839
FINANCING ACTIVITIES:
Principal payments for financing leases	(327)		(958)
Proceeds from issuance of common stock in connection with the exercise of options and ESPP	122		854
Payments on repurchase of convertible senior notes	(72,492)		(149,702)
Net cash used in financing activities	(72,697)		(149,806)
Effect of foreign exchange rate changes on cash and cash equivalents	400		2,849
Net decrease in cash, cash equivalents, and restricted cash	(83,908)		(150,036)
Cash, cash equivalents, and restricted cash - beginning of year	212,925		392,197


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Plus: cash classified within current assets held for sale - beginning of year	—		10,011
Cash, cash equivalents, and restricted cash - end of period	$	129,017	$	252,172

Reconciliation of cash, cash equivalents, and restricted cash to condensed consolidated balance sheets
Cash and cash equivalents	$	127,057	$	239,975
Restricted cash	1,960		12,197
Total cash, cash equivalents, and restricted cash - end of period	$	129,017	$	252,172

Supplemental disclosure of other cash flow information:
Cash paid for income taxes, net	$	451	$	187
Cash paid for interest	292		888
Supplemental disclosure of non-cash investing and financing activities:
Purchase of property and equipment and intangible assets recorded in accounts payable	$	50	$	790

See accompanying notes to condensed consolidated financial statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Description of Business and Basis of Presentation

LivePerson, Inc. (“LivePerson”, the “Company”, “we”, “our” or “us”) is the enterprise leader in digital customer conversation. Over the past two decades, consumers have made digital conversations a primary way to communicate with others. Since 1998, we have enabled meaningful connections between consumers and our customers through our platform and currently power more than one billion connections and conversations each month. These digital and artificial intelligence (“AI”)-powered conversations decrease costs and increase revenue for our brands, resulting in more convenient, personalized and content-rich journeys across the entire consumer lifecycle, and across consumer channels. AI has accelerated our capability to leverage prior conversations and our customers’ existing investments in Generative AI and Large Language Models (“LLMs”) to enhance the consumer experience and to improve results for our customers by empowering them to leverage the latest developments in AI and LLMs, in a safe and secure environment.

The Conversational Cloud, the Company’s enterprise-class digital customer conversation platform, is trusted by the world’s top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The Conversational Cloud powers conversations across each of a brand’s primary digital channels, including mobile apps, mobile and desktop web browsers, short messaging service (“SMS”), social media and third-party consumer messaging platforms. Brands can also use the Conversational Cloud to message consumers when they dial a 1-800 number instead of forcing them to navigate interactive voice response systems and wait on hold. Most recently, the Conversational Cloud has been enhanced to provide a secure platform with appropriate guardrails to deploy Generative AI and LLMs in ways that help consumers and drive results for brands without sacrificing trust.

LivePerson’s digital customer conversation platform enables what the Company calls “the tango” of humans, LivePerson bots, third-party bots and LLMs, whereby humans act as bot managers, overseeing AI-powered conversations and seamlessly stepping into the flow when a personal touch is needed. Agents become highly efficient, leveraging the AI engine (including generative AI capabilities) to surface relevant content, define next-best actions and take over repetitive transactional work so that the agent can focus on relationship building. By seamlessly integrating messaging with the Company’s proprietary Conversational AI, as well as bots, the Conversational Cloud offers brands a comprehensive approach to scaling automations across their millions of customer conversations.

Basis of Presentation

The accompanying condensed consolidated financial statements, and the financial data and other information disclosed in the notes to the condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 are unaudited. In the opinion of management, the unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position, results of operations, comprehensive loss, and cash flows for the interim periods presented. The results of operations for any interim period are not necessarily indicative of the results of operations for any other future interim period or for a full fiscal year. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at that date.

Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 4, 2024.

Principles of Consolidation

The unaudited condensed consolidated financial statements reflect the operations of LivePerson and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. These estimates are based on information available as of the date of the condensed consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions.

Items subject to such estimates and assumptions include, but are not limited to:

•stock-based compensation expense;

•allowance for credit losses;

•the period of benefit for deferred contract acquisition costs;

•valuation of goodwill;

•valuation and useful lives of other long-lived assets;

•fair value of assets acquired and liabilities assumed in business combinations;

•income taxes; and

•recognition, measurement, and disclosure of contingent liabilities.

As of the date of issuance of the financial statements, the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.

Significant Accounting Policies

The Company’s significant accounting policies are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. There have been no significant changes to these policies that have had a material impact on the Company’s condensed consolidated financial statements and related notes for the three months ended March 31, 2024.

Prepaid expenses and other current assets

The following table presents the detail of prepaid expenses and other current assets as of the dates presented:


	March 31, 2024		December 31, 2023

	(In thousands)
Prepaid software maintenance	$	6,065	$	8,592
VAT receivable	4,168		4,399
Prepaid server maintenance	2,824		2,634
Prepaid - other	2,743		2,599
Other assets	5,154		8,757
Total prepaid expenses and other current assets	$	20,954	$	26,981

Recently Adopted Accounting Pronouncements

In June 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions to clarify that a contractual restriction on the sale of an equity security is not considered part of a unit of account of the equity security, and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments also require the following disclosures for equity securities subject to the contractual sale restrictions: 1.) The fair value of equity securities subject to the contractual sale restrictions reflected on the balance sheet. 2.) The nature and remaining duration of the restriction(s). 3.) The

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

circumstances that could cause a lapse in the restriction(s). This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within those financial years. The Company adopted this guidance on January 1, 2024, which did not have a material effect on the Company’s condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

On March 21, 2024, the FASB issued ASU 2024-01, Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, which provides illustrative guidance to help entities determine whether profits interest and similar awards should be accounted for as share-based payment arrangements within the scope of FASB Accounting Standards Codification (“ASC”) 718, “Compensation—Stock Compensation.” Specifically, the amendments in ASU 2024-01 add an illustrative example that includes four fact patterns to demonstrate how an entity should apply the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic 718. The guidance in ASU 2024-01 applies to all entities that issue profits interest awards as compensation to employees or non-employees in exchange for goods or services. The amendments in this update are effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. ASU 2024-01 should be applied either retrospectively or prospectively. The Company does not expect this this standard to have a material impact on its condensed consolidated financial statements and related disclosures.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The updated standard is effective for annual periods beginning after December 15, 2023. The Company is currently evaluating the potential impact of adopting this new guidance on its condensed consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. The Company does not expect this standard to have a material impact on its condensed consolidated financial statements and related disclosures.

In August 2023, the FASB issued ASU 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement, which addresses the accounting for contributions made to a joint venture, upon formation, in a joint venture’s separate financial statements. The amendments require certain joint ventures to apply a new basis of accounting upon formation by recognizing and initially measuring most of their assets and liabilities at fair value. The objectives of the amendments are to provide decision-useful information to investors and other allocators of capital in a joint venture’s financial statements and also to reduce diversity in practice. ASU 2023-05 is effective for both public and private joint venture entities with a formation date on or after January 1, 2025. Early adoption is permitted. Entities may elect to apply the guidance retrospectively to joint ventures with a formation date prior to January 1, 2025. The Company does not expect the adoption of this standard to have a material impact on its condensed consolidated financial statements and related disclosures.

Note 2. Revenue Recognition

The majority of the Company’s revenue is generated from hosted service revenues, which is inclusive of its platform pricing model, and related professional services. Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. No single customer accounted for 10% or more of total revenue for the three months ended March 31, 2024 and 2023.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table presents the Company’s revenues disaggregated by revenue source:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Revenue:
Hosted services (1)	$	71,495	$	87,338
Professional services	13,654		20,323
Total revenue	$	85,149	$	107,661

(1)On March 20, 2023, the Company completed the sale of Kasamba and therefore ceased recognizing revenue related to Kasamba effective on the transaction close date. Further, this sale eliminated the entire Consumer segment, as a result of which revenue is presented within a single condensed consolidated segment. Hosted services includes $7.2 million of revenue for the three months ended March 31 2023, relating to Kasamba.

Remaining Performance Obligation

As of March 31, 2024, the aggregate amount of the total transaction price allocated in contracts with original duration of one year or greater to the remaining performance obligations was $296.7 million. Approximately 91% of the Company’s remaining performance obligations is expected to be recognized during the next 24 months, with the balance recognized thereafter. The aggregate balance of unsatisfied performance obligations represents contracted revenue that has not yet been recognized, and does not include contract amounts that are cancellable by the customer, amounts associated with optional renewal periods, and any amounts related to performance obligations, which are billed and recognized as they are delivered. The Company has elected the optional exemption, which allows for the exclusion of the amounts for remaining performance obligations that are part of contracts with an original expected duration of less than one year. Such remaining performance obligations represent unsatisfied or partially unsatisfied performance obligations pursuant to ASC 606, “Revenue from Contracts with Customers.”

Revenue by Geographic Location

The Company is domiciled in the United States and has international operations around the globe. The following table presents the Company’s revenues attributable to domestic and foreign operations for the periods presented:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
United States	$	60,507	$	68,509
Other Americas (1)	1,518		3,805
Total Americas	62,025		72,314
EMEA (2) (3)	14,221		16,182
APAC (4)	8,903		19,165
Total revenue	$	85,149	$	107,661

——————————————

(1)Canada, Latin America and South America

(2)Europe, the Middle East and Africa (“EMEA”)

(3)Includes revenue from the United Kingdom of $10.7 million and $15.3 million for the three months ended March 31, 2024 and 2023, respectively.

(4)Asia-Pacific (“APAC”)

Information about Contract Balances

The deferred revenue balance consists of services, which have been invoiced upfront, and are recognized as revenue only when the revenue recognition criteria are met.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

In some arrangements, the Company allows customers to pay for access to the Conversational Cloud over the term of the software license. The Company refers to these as subscription transactions. Amounts recognized as revenue in excess of amounts billed are recorded as unbilled receivables. Unbilled receivables, anticipated to be invoiced in the next twelve months, are included in accounts receivable, net of allowance for credit losses on the condensed consolidated balance sheets.

The Company recognized revenue of $42.5 million and $44.1 million for the three months ended March 31, 2024 and 2023, respectively, which was included in the corresponding deferred revenue balance at the beginning of the year.

The deferred revenue balance consists of services, which have been invoiced upfront, and are recognized as revenue only when the revenue recognition criteria are met. Our long-term deferred revenues are included in Other liabilities on the condensed consolidated balance sheets. The opening and closing balances of the Company’s accounts receivable, unbilled receivables, and deferred revenues are as follows:


	Accounts Receivable		Unbilled Receivable		Contract Acquisition Costs, Net (Non-current)		Deferred Revenue (Current)		Deferred Revenue (Non-current)

	(In thousands)
Balance as of December 31, 2022	$	53,468	$	33,069	$	43,804	$	84,494	$	174
Increase (decrease), net	6,914		(11,649)		(6,450)		(2,636)		9
Balance as of December 31, 2023	$	60,382	$	21,420	$	37,354	$	81,858	$	183
Increase (decrease), net	(6,177)		(4,260)		1,972		10,556		(60)
Balance as of March 31, 2024	$	54,205	$	17,160	$	39,326	$	92,414	$	123

Amortization expense in connection with contract acquisition cost was approximately $4.9 million and $8.3 million for the three months ended March 31, 2024 and 2023, respectively.

Accounts Receivable, Net

Accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for credit losses is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable, based on both specific and general reserves. The Company maintains general reserves on a collective basis by considering factors such as historical experience, creditworthiness, the age of the trade receivable balances, and current economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance sheet credit exposure related to its customers. The activity in the allowance for credit losses is as follows:


	March 31, 2024		December 31, 2023

	(In thousands)
Balance, beginning of year	$	9,290	9,239
Additions charged to costs and expenses	4,722		3,319
Deductions/write-offs	(4,777)		(3,268)
Balance, end of period	$	9,235	$	9,290

Note 3. Net Loss Per Share

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Basic earnings per share (“EPS”) excludes dilution for common stock equivalents and is computed by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted EPS is calculated based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period. Potentially dilutive securities consist of common stock options, restricted stock units, contingently issuable shares and convertible securities. The dilutive effect of stock options, restricted stock units and contingently issuable shares is reflected in diluted EPS by application of the treasury stock method. The dilutive effect of convertible securities is reflected in the diluted EPS by application of the “if-converted” method. The “if-converted” method is only assumed in periods where such application would be dilutive. In applying the “if-converted” method for diluted EPS, the Company would assume conversion of the 0.750% Convertible Senior Notes due 2024 (“2024 Notes”) at a ratio of 25.9182 shares of its common stock per $1,000 principal amount of the 2024 Notes. Assumed converted shares of the Company’s common stock are weighted for the period the 2024 Notes were outstanding. In applying the “if-converted” method for diluted EPS, the Company would assume conversion of its 0% Convertible Senior Notes due 2026 at a ratio of 13.2933 shares of its common stock per $1,000 principal amount of such notes. See Note 8 – Convertible Senior Notes, Net of Current Portion and Capped Call Transactions for additional information about the 2024 Notes and 2026 Notes.

The following table presents shares used in calculating basic and diluted EPS for the three months ended March 31, 2024 and 2023, as follows:


	Three Months Ended March 31,
	2024		2023

	(In thousands, except per share amounts)
Net loss	$	(35,631)	$	(17,420)
Weighted average number of shares outstanding, basic and diluted	88,081,654		75,774,812
Net loss per share, basic and diluted	$	(0.40)	$	(0.23)

Further, the following securities were excluded from the computation of diluted EPS, as their effect would have been anti-dilutive:


	As of March 31,
	2024	2023
Shares subject to outstanding common stock options and employee stock purchase plan	3,251,520	4,078,938
Restricted stock units	8,052,908	4,331,255
Earn-outs	—	23,818,594
Conversion option of the 2024 Notes	—	1,878,862
Conversion option of the 2026 Notes	6,879,283	6,879,283
Total	18,183,711	40,986,932

Note 4. Segment Information

The Company accounts for its segment information in accordance with the provisions of ASC 280-10, “Segment Reporting.” ASC 280-10 establishes annual and interim reporting standards for operating segments of a company. ASC 280-10 requires disclosures of selected segment-related financial information about products, major customers, and geographic areas based on the Company’s internal accounting methods. The chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, evaluates performance, makes operating decisions, and allocates resources based on the financial information presented on a consolidated basis. Accordingly, management has determined that the Company operates as one operating and reportable segment.

The Company was previously organized into two operating segments for purposes of making operating decisions and assessing performance: the Business segment and the Consumer segment. During the first quarter of 2023, the Consumer segment (consisting solely of the Kasamba business) was divested. As a result, the divestiture of Kasamba eliminated the Company’s Consumer segment. See Note 19 – Divestiture for additional information.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Geographic Information

The Company is domiciled in the United States and has international operations around the globe. The following table presents the Company’s long-lived assets by geographic region as of March 31, 2024 and December 31, 2023:


	March 31,		December 31,
	2024		2023

	(In thousands)
United States	$	430,731	$	438,420
Germany	41,778		45,424
Australia	11,865		11,660
Netherlands	5,843		5,863
Other (1)	13,135		12,438
Total long-lived assets	$	503,352	$	513,805

——————————————

(1)United Kingdom, Japan, France, Italy, Spain, Canada, and Singapore

Note 5. Goodwill and Intangible Assets, Net

Goodwill

Goodwill represents the excess of the aggregate purchase price over the fair value of net identifiable assets acquired in a business combination. Goodwill is not amortized, but is tested for impairment at the reporting unit level using either a qualitative or quantitative assessment on an annual basis, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In the valuation of goodwill, management must make assumptions regarding estimated future cash flows to be derived from the Company’s business. If these estimates or their related assumptions change in the future, the Company may be required to record impairment for these assets.

The changes in the carrying amount of goodwill as of March 31, 2024 and December 31, 2023 are as follows:


	Consolidated

	(In thousands)
Balance as of December 31, 2022	$	296,214
Adjustments to goodwill:
Goodwill impairment (1)	(11,895)
Foreign exchange adjustment	1,312
Balance as of December 31, 2023	$	285,631
Adjustments to goodwill:

Goodwill impairment (1)	(3,627)
Foreign exchange adjustment	(1,048)
Balance as of March 31, 2024	$	280,956

(1) These amounts represent the entire accumulated goodwill impairment balance as of March 31, 2024.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

As a result of the Company’s intention to sell or dispose of its WildHealth reporting unit, the Company recorded a non-cash impairment charge of $3.6 million in the condensed consolidated statements of operations during the three months ended March 31, 2024, to recognize a full impairment of goodwill associated with its WildHealth reporting unit. There were no impairments in the Company’s Business reporting unit during the three months ended March 31, 2024. There were no impairments of goodwill during the three months ended March 31, 2023.

Intangible Assets, Net

Intangible assets are summarized as follows:


	March 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Amortization Period

	(In thousands)						(In years)
Amortizing intangible assets:
Technology	$	94,562	$	(65,107)	$	29,455	5.0
Customer relationships	32,060		(20,057)		12,003		10.0
Patents	15,895		(2,066)		13,829		12.9
Trademarks	1,404		(761)		643		5.0
Trade names	1,044		(1,044)		—		2.8
Other	914		(835)		79		4.1
Total	$	145,879	$	(89,870)	$	56,009


	December 31, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Amortization Period

	(In thousands)						(In years)
Amortizing intangible assets:
Technology	$	94,549	$	(60,465)	$	34,084	5.0
Customer relationships	32,025		(19,542)		12,483		10.0
Patents	15,350		(1,916)		13,434		12.9
Trademarks	1,400		(707)		693		5.0
Trade names	1,044		(672)		372		2.8
Other	914		(355)		559		4.1
Total	$	145,282	$	(83,657)	$	61,625

Amortization expense is calculated over the estimated useful life of the asset. Aggregate amortization expense for intangible assets and finance leases, net was $4.2 million and $5.4 million for the three months ended March 31, 2024 and 2023, respectively. Amortization expense included in cost of revenue in our condensed consolidated statements of operations was $3.3 million and $4.6 million for the three months ended March 31, 2024 and 2023, respectively.

As a result of our impairment test in the first quarter of 2024, the Company recognized an immaterial non-cash impairment charge of $2.2 million included in impairment of intangibles and other assets in the condensed consolidated statements of operations, related to intangible assets associated with its WildHealth reporting unit, due to a plan to sell or dispose of the WildHealth reporting unit, as discussed above. There were no impairments of intangible assets during the three months ended March 31, 2023.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

As of March 31, 2024, estimated annual amortization expense for the next five years and thereafter is as follows:


	Estimated Amortization Expense
	(In thousands)
Remainder of 2024	$	11,567
2025	14,996
2026	12,160
2027	1,004
2028	821
Thereafter	15,461
Total	$	56,009

Note 6. Property and Equipment, Net

Property and equipment are stated at cost, net of accumulated depreciation, and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the asset. The Company reviews the estimated useful lives of its property and equipment on an ongoing basis. The following table presents the detail of property and equipment, net for the periods presented:


	March 31, 2024		December 31, 2023		Useful life

	(In thousands)				(In years)
Internal-use software development costs	$	186,746	$	181,079	5
Computer equipment and software	126,728		123,580		3 to 5
Furniture, equipment and building improvements	329		327		The lesser of 5 or estimated useful life
Finance lease right-of-use assets	128		3,060		2
Property and equipment, at cost	313,931		308,046
Less: accumulated depreciation	(196,038)		(188,721)
Property and equipment, net	$	117,893	$	119,325

Depreciation and amortization expense of property and equipment was $8.2 million and $7.4 million during the three months ended March 31, 2024 and 2023, respectively.

Expenditures for routine maintenance and repairs are charged to operating expense as incurred. Major renewals and improvements are capitalized and depreciated over their estimated useful lives.

There were no impairments of property and equipment during the three months ended March 31, 2024 and 2023.

Total depreciation included in our condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 is as follows:

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)


	March 31, 2024		March 31, 2023

	(In thousands)
Cost of revenue	$	1,682	$	2,247
Sales and marketing	900		726
General and administrative	158		161
Product development	5,485		4,228
Total	$	8,225	$	7,362

Note 7. Accrued Expenses and Other Current Liabilities

The following table presents the detail of accrued expenses and other current liabilities for the periods presented:


	March 31, 2024		December 31, 2023

	(In thousands)
Professional services and consulting and other vendor fees	$	56,593	$	67,585
Payroll and other employee-related costs	13,214		20,767
Finance lease liability	104		3,037
Restructuring	1,808		2,076
Sales commissions	1,645		734
Non-income tax	556		556

Other	1,586		2,269
Total	$	75,506	$	97,024

Note 8. Convertible Senior Notes, Net of Current Portion and Capped Call Transactions

Convertible Senior Notes due 2024 and Capped Calls

In March 2019, the Company issued $230.0 million aggregate principal amount of its 0.750% Convertible Senior Notes due 2024 (the “2024 Notes”) in a private placement. Interest on the 2024 Notes was payable semi-annually in arrears on March 1 and September 1 of each year. The 2024 Notes matured on March 1, 2024, on which date the Company repaid in full the outstanding $72.5 million in aggregate principal amount of the 2024 Notes.

On March 21, 2023, the Company entered into individual privately negotiated transactions (the “Note Repurchase Agreements”) with certain holders of its 2024 Notes, pursuant to which the Company agreed to pay an aggregate of approximately $149.7 million in cash for the repurchase of approximately $157.5 million in aggregate principal amount of the 2024 Notes (the “Note Repurchases”). During the first quarter of 2023, the Company recognized a $6.1 million gain, net of transaction costs of $0.5 million on debt extinguishment, which represented the difference between the carrying value and the fair value of the 2024 Notes just prior to the Note Repurchases, which was recorded in Other (expense) income, net in the condensed consolidated statements of operations. The gain on debt extinguishment was subsequently adjusted by an immaterial amount of $1.1 million with a total gain of $7.2 million reported as of December 31, 2023.

Upon completion of the Note Repurchases, the aggregate principal amount of the 2024 Notes was reduced by $157.5 million to $72.5 million and the carrying amount of the 2024 Notes reduced by $228.3 million to $72.0 million. A corresponding portion of the 2024 capped calls were terminated in connection following the Note Repurchases as required by their terms for minimal consideration.

As of March 31, 2024, there was no outstanding principal amount of the 2024 Notes.

Convertible Senior Notes due 2026 and Capped Calls

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

In December 2020, the Company issued $517.5 million aggregate principal amount of its 0% Convertible Senior Notes due 2026 (the “2026 Notes” and together with the 2024 Notes, the “Notes”) in a private placement.

The 2026 Notes will mature on December 15, 2026, unless earlier repurchased or redeemed by the Company or converted pursuant to their terms. The total net proceeds from the offering of the 2026 Notes, after deducting debt issuance costs, was approximately $505.3 million.

Each $1,000 in principal amount of the 2026 Notes is initially convertible into 13.2933 shares of the Company’s common stock par value $0.001, which is equivalent to an initial conversion price of approximately $75.23 per share. The conversion rate is subject to adjustment upon the occurrence of certain specified events but will not be adjusted for any accrued and unpaid special interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its 2026 Notes in connection with such a corporate event. The 2026 Notes are not redeemable prior to the maturity date of the 2026 Notes and no sinking fund is provided for the 2026 Notes. If the Company undergoes a fundamental change (as defined in the indenture governing the 2026 Notes), which includes the failure of our common stock to be listed or quoted on any of the Nasdaq Global Select Market, The Nasdaq Global Market or the New York Stock Exchange, holders may require the Company to repurchase for cash all or any portion of their 2026 Notes in principal amounts of $1,000 or a multiple thereof at a fundamental change repurchase price equal to 100% of the principal amount of the 2026 Notes to be repurchased, plus accrued and unpaid special interest to, but excluding, the fundamental change repurchase date.

Holders of the 2026 Notes may convert their 2026 Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2026, in multiples of $1,000 principal amount, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2021 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2026 Notes on each applicable trading day as determined by the Company; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the “trading price” (as defined in the indenture governing the 2026 Notes) per $1,000 principal amount of 2026 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the 2026 Notes on each such trading day; (3) with respect to any 2026 Notes that the Company calls for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after August 15, 2026, holders may convert all or any portion of their 2026 Notes at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company’s election.

During the three months ended March 31, 2024, the conditions allowing holders of the 2026 Notes to convert were not met.

The 2026 Notes are senior unsecured obligations of the Company.

As a result of the adoption of ASU 2020-06, the 2026 Notes are accounted for as a single liability, and the carrying amount of the 2026 Notes is $512.1 million as of March 31, 2024, consisting of principal of $517.5 million, net of unamortized issuance costs of $5.4 million. The 2026 Notes were classified as long term liabilities in the accompanying condensed consolidated balance sheets as of March 31, 2024. The remaining term over which the 2026 Notes’ debt issuance costs will be amortized is 2.7 years at an effective interest rate of 0.40% for the three months ended March 31, 2024.

In connection with the offering of the 2026 Notes, the Company entered into privately-negotiated capped call option transactions with certain counterparties (the “2026 capped calls”). The 2026 capped calls each have an initial strike price of approximately $75.23 per share, subject to certain adjustments, which corresponds to the initial conversion price of the 2026 Notes. The 2026 capped calls have initial cap prices of $105.58 per share, subject to certain adjustment events. The 2026 capped calls cover, subject to anti-dilution adjustments, approximately 6.88 million shares of common stock. The 2026 capped calls are generally intended to reduce or offset the potential dilution to the common stock upon any conversion of the 2026 Notes with such reduction or offset, as the case may be, subject to a cap based on the cap price. The 2026 capped calls expire on December 15, 2026, subject to earlier exercise. The 2026 capped calls are subject to either adjustment or termination upon the occurrence of specified extraordinary events affecting the Company, including a merger event, a tender offer, and a

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

nationalization, insolvency or delisting involving the Company. In addition, the 2026 capped calls are subject to certain specified additional disruption events that may give rise to a termination of the 2026 capped calls, including changes in law, failure to deliver, and hedging disruptions. The 2026 capped calls are recorded in stockholders’ equity and are not accounted for as derivatives. The net cost of $46.1 million incurred to purchase the 2026 capped calls was recorded as a reduction to additional paid-in capital in the accompanying condensed consolidated balance sheets.

Unamortized debt issuance costs incurred in connection with securing the Company’s financing arrangements are presented in the condensed consolidated balance sheets as a direct deduction from the carrying amount of the outstanding borrowings, consistent with debt discounts. All deferred financing costs are amortized to interest expense. The net carrying amount of the liability component of the Notes as of March 31, 2024 and December 31, 2023 is as follows:


	March 31, 2024		December 31, 2023

	(In thousands)
Principal	$	517,500	$	589,992
Unamortized issuance costs	(5,424)		(6,034)
Total net carrying value	$	512,076	$	583,958
Less: short-term debt, net	—		72,393
Long-term debt, net	$	512,076	$	511,565

The following table sets forth the interest expense recognized related to the Notes:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Contractual interest expense	$	91	$	441
Amortization of debt issuance costs	610		920
Total interest expense	$	701	$	1,361

Interest expense of $0.7 million and $1.4 million is reflected as a component of interest expense, net in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, respectively.

Note 9. Leases

The Company has non-cancelable operating and finance leases for its corporate offices and other service agreements. Its leases have remaining lease terms of less than one to five years, some of which include options to extend. The Company uses the non-cancelable lease term when recognizing the right-of-use (“ROU”) assets and lease liabilities, unless it is reasonably certain that a renewal or termination option will be exercised.

The Company continues to actively assess its global lease portfolio. However, any additional de-recognition of ROU assets and incurrence of various one-time expenses in connection with early termination of additional leases are not expected to be material to its financial condition or results of operations.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Supplemental cash flow information related to leases for the periods ended March 31, 2024 and 2023 is as follows:


	Three Months Ended
	March 31,
	2024		2023

	(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	842	$	974
Operating cash flows for finance leases	18		24
Financing cash flows for finance leases	327		958

The components of lease costs for the periods ended March 31, 2024 and 2023 are as follows:


	Three Months Ended
	March 31,
	2024		2023

	(In thousands)
Finance lease cost
Amortization of right of use assets	$	334	$	911
Interest	18		24
Operating lease cost	2,902		2,740
Total lease cost	$	3,254	$	3,675


	March 31, 2024		March 31, 2023
Weighted Average Remaining Lease Term:
Operating leases	2.0 years		1.7 years
Finance leases	1.6 years		1.0 year

Weighted Average Discount Rate:
Operating leases	7	%	7	%
Finance leases	7	%	4	%

Supplemental balance sheet information related to leases is as follows:

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)


	Financial Statement Classification	March 31, 2024		December 31, 2023

		(In thousands)
Assets
Operating right-of-use assets	Operating lease right-of-use assets	$	3,431	$	4,135
Finance right-of-use assets	Property and equipment, net	128		3,060

Liabilities
Current liabilities:
Operating lease liabilities	Operating lease liabilities	$	2,632	$	2,719
Finance lease liabilities	Accrued expenses and other current liabilities	104		3,037
Non-current liabilities:
Operating lease liabilities	Operating lease liabilities, net of current portion	1,466		2,173
Finance lease liabilities	Other liabilities	55		85

Future minimum lease payments under non-cancellable operating and finance leases (with an initial or remaining lease term in excess of one year) are as follows:


	March 31, 2024
	Operating Leases		Finance Leases

	(In thousands)
2024 (remaining nine months for March 31, 2024)	$	2,186	$	83
2025	1,689		83
2026	316		—
2027	172		—
2028	86		—
Thereafter	—		—
Total minimum lease payments	4,449		166
Less: present value adjustment	(351)		(7)
Present value of lease liabilities	$	4,098	$	159

Note 10. Fair Value Measurements

The Company measures its cash equivalents at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value:

•Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

•Level 2: Inputs reflect: quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

•Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

Financial Assets and Liabilities

The carrying amount of cash, accounts receivable, and accounts payable approximate their fair value due to their short-term nature. The Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy as of March 31, 2024 and December 31, 2023, are summarized as follows:


	March 31, 2024
	Level 1		Level 2		Level 3		Total

	(In thousands)
Assets
Cash equivalents:
Money market funds	$	84,990	$	—	$	—	$	84,990
Total assets	$	84,990	$	—	$	—	$	84,990


	December 31, 2023
	Level 1		Level 2		Level 3		Total

	(In thousands)
Assets
Cash equivalents:
Money market funds	$	174,701	$	—	$	—	$	174,701
Total assets	$	174,701	$	—	$	—	$	174,701

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. Observable or market inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s assumptions based on the best information available.

The Company’s money market funds are measured at fair value on a recurring basis based on quoted market prices in active markets and are classified as Level 1 within the fair value hierarchy. The Company’s contingent earn-out liability was measured at fair value on a recurring basis and was classified as Level 3 within the fair value hierarchy. For 2023, the fair value was based on the negotiated contracts with the selling shareholders. Significant changes in unobservable inputs could result in significantly lower or higher fair value measurements.

On a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value. The Company uses an income approach and inputs that constitute Level 3.

The estimated fair value of outstanding balances of our 2024 Notes and 2026 Notes are as follows:

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)


	Level of Hierarchy	Fair Value		Principal Balance		Unamortized Issuance Costs		Net Carrying Value

		(In thousands)
March 31, 2024
2026 Notes	2	$	367,497	$	517,500	$	(5,424)	$	512,076
December 31, 2023
2024 and 2026 Notes	2	$	435,883	$	589,992	$	(6,034)	$	583,958

Management determines the fair value by using Level 2 inputs based on antithetic variable technique done by an independent valuation specialist. Refer to Note 8 – Convertible Senior Notes, Net of Current Portion and Capped Call Transactions for additional information.

The Company did not have Level 3 liabilities during the three months ended March 31, 2024. The changes in fair value of the Level 3 liabilities during the annual period ended December 31, 2023 are as follows:


	December 31, 2023


Balance, beginning of year	$	72,221
Additions in the period	—
Change in fair value of contingent consideration	4,629
Change in fair value of liability awards	(27,857)
Payments	(48,993)
Balance, end of year	$	—

Certain former stakeholders of the Company’s acquisitions were eligible to receive additional cash or share considerations based on the attainment of certain operating metrics in the periods subsequent to the acquisitions. These earn-out arrangements were accounted for as either contingent considerations arrangements or compensation arrangements. Contingent considerations were fair valued using significant inputs that are not observable in the market.

The earn-outs determined to be compensatory were remeasured each reporting period based on whether the performance targets were probable of being achieved and recognized over the related service periods. During the year ended December 31, 2023, the Company settled the VoiceBase, Tenfold and e-Bot7 and WildHealth, Inc. earn-outs for approximately $19.9 million, $9.3 million, $7.7 million, and $12.0 million, respectively.

Changes to the fair value of the earnouts were recognized as a component of stock-based compensation expense and other income (expense), net in the accompanying condensed consolidated statements of operations. Payments in cash were recognized as a component of compensation expense and payments in stock were recognized as a component of equity in the accompanying condensed consolidated statements of operations. There were no outstanding earnout liabilities as of March 31, 2024 based on settlements that were completed as of December 31, 2023.

Note 11. Commitments and Contingencies

Employee Benefit Plans

The Company has a 401(k) defined contribution plan covering all eligible employees. The Company’s 401(k) policy is a Safe Harbor Plan, whereby the Company matches 100% of the first 3% of eligible compensation and 50% of the next 2% of eligible compensation. Furthermore, the match is immediately vested. Salaries and related expenses include $1.1 million and $1.4 million of employer matching contributions for the three months ended March 31, 2024 and 2023, respectively.

Letters of Credit

As of March 31, 2024, the Company had letters of credit totaling $0.5 million outstanding as a security deposit for the due performance by the Company of the terms and conditions of a supply contract.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Contractual obligations

The Company’s purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. These purchase obligation agreements are primarily related to contracts with vendors in connection with Information Technology (“IT”) infrastructure and cloud computing-related services with remaining terms of two years or less. Our contractual obligations as of March 31, 2024, did not materially change from the amounts disclosed in our 2023 Annual Report on Form 10-K.

Indemnifications

The Company enters into service and license agreements in its ordinary course of business. Pursuant to some of these agreements, the Company agrees to indemnify certain customers from and against certain types of claims and losses suffered or incurred by them as a result of using the Company’s products.

The Company also has agreements whereby its executive officers and directors are indemnified for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a directors and officers insurance policy that reduces its exposure and enables the Company to recover a portion of any future amounts paid subject to customary deductibles. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. The Company has no liabilities recorded for these agreements as of March 31, 2024 and December 31, 2023.

Non-Income Related Taxes

The Company is subject to sales tax liabilities, plus applicable interest, for states in which it has an economic nexus. The accrual balance for sales tax liabilities included within the condensed consolidated balance sheets was $0.6 million as of March 31, 2024 and December 31, 2023.

Note 12. Stockholders’ Equity

Stock-Based Compensation

The Company’s stock-based compensation generally includes stock options, restricted stock units (“RSUs”), performance-vesting restricted stock units (“PRSUs”), and purchases under the Company’s 2019 Employee Stock Purchase Plan. Stock-based compensation expense related to RSUs is based on the market value of the underlying stock on the date of grant and the related expense is recognized ratably over the requisite service period. The stock-based compensation expense related to PRSUs is estimated at the grant date based on the expectation that performance goals will be achieved at the stated target level. The amount of compensation cost recognized depends on the relative satisfaction of the performance condition based on performance to date.

Stock Option Plans

The Company’s 2019 Stock Incentive Plan became effective on April 11, 2019. The 2019 Stock Incentive Plan, as amended and restated, allows the Company to grant incentive stock options and restricted stock units to its employees and directors to participate in the Company’s future performance through stock-based awards at the discretion of the board of directors. The number of shares authorized for issuance as of March 31, 2024 was 42,367,744 shares in the aggregate. Options to acquire common stock granted thereunder have ten-year terms. As of March 31, 2024, 2,286,084 shares of common stock remained available for issuance (taking into account all option exercises and other equity award settlements through March 31, 2024).

Employee Stock Purchase Plan

As of March 31, 2024, there were 2,000,000 shares authorized and reserved for issuance under the 2019 ESPP. As of March 31, 2024, 948,453 shares of common stock remained available for issuance under the ESPP (taking into account all share purchases through March 31, 2024).

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Inducement Plan

There are 11,459,009 shares of common stock authorized and reserved for issuance under the 2018 Inducement Plan. On March 8, 2024, the Company’s board of directors amended the plan and authorized 5,300,000 new shares for issuance. As of March 31, 2024, 5,994,216 shares of common stock remained available for issuance under the Inducement Plan (taking into account all option exercises and other equity award settlements through March 31, 2024).

Stock Option Activity

The following table is a summary of the Company’s stock option activity for the three months ended March 31, 2024:


	Stock Option Activity				Weighted Average Remaining Contractual Term (In years)	Aggregate Intrinsic Value (In thousands)
	Options (In thousands)		Weighted Average Exercise Price
Balance outstanding at December 31, 2023	3,137		$	22.68	4.84	$	40
Granted	1,000	(1)	1.02
Exercised	—		—
Cancelled or expired	(885)		23.65
Balance outstanding at March 31, 2024	3,252		15.75		5.99	3
Options vested and expected to vest	647		9.30		3.71	—
Options exercisable at March 31, 2024	1,977		$	21.56	9.35	$	3

(1) Represents a stock option award, granted to the Company’s new Chief Executive Officer, to acquire shares of the Company’s common stock that will vest upon the satisfaction of certain performance-based and time-based vesting conditions. This award, provided for under the terms of the Chief Executive Officer’s employment agreement, was approved by the Compensation Committee of the Company’s board of directors (the “Board”) as a standalone inducement award under applicable Nasdaq rules and does not count against the number of shares reserved for issuance under the Company’s 2019 Stock Incentive Plan or the Company’s 2018 Inducement Plan.

As of March 31, 2024, there was approximately $2.8 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements. That cost is expected to be recognized over a weighted average period of approximately 1.9 years.

Restricted Stock Unit and Performance-Vesting Restricted Stock Unit Activity

The following table is a summary of the Company’s RSUs and PRSUs activity for the three months ended March 31, 2024:


	Number of Shares	Weighted Average Grant Date Fair Value		Aggregate Fair Value

	(In thousands)	(Per share)		(In thousands)
Balance outstanding at December 31, 2023	5,064	$	12.53	$	19,193
Awarded	3,893	1.17
Vested	(433)	16.94
Forfeited	(471)	16.61
Non-vested and outstanding at March 31, 2024	8,053	6.56		7,879
Expected to vest	5,285	$	7.02	$	5,153

RSUs granted to employees generally vest over a three to four-year period or upon achievement of certain performance conditions. As of March 31, 2024, total unrecognized compensation cost, adjusted for estimated forfeitures, related to nonvested RSUs and PRSUs was approximately $37.7 million and the weighted-average remaining vesting period was 1.9 years.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

PRSUs granted are generally subject to both a service-based vesting condition and a performance-based vesting condition. PRSUs will vest upon the achievement of specified performance targets and subject to continued service through the applicable vesting dates. The associated compensation cost is recognized over the requisite service period when it is probable that the performance condition will be satisfied. There were no PRSUs granted during the three months ended March 31, 2024. PRSUs granted during the three months ended March 31, 2023 were immaterial.

Total stock-based compensation costs included in our condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 are as follows:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Cost of revenue	$	343	$	2,035
Sales and marketing	2,455		2,404
General and administrative	1,798		2,632
Product development	2,962		4,261
Total	$	7,558	$	11,332

Note 13. Restructuring

During the second quarter of 2022, LivePerson began a restructuring initiative to realign the Company’s cost structure to better reflect significant product and business model innovation and then-recent changes due to acquisitions and factors outside the control of the Company. As part of the restructuring initiative, the Company reoriented its global product and engineering organization for greater efficiency and focus, and reallocated some spending to increase its investment in customer success and go-to-market initiatives. In 2023, due to the changing technology landscape related to the evolution of LLMs, we were able to identify opportunities for significant cost savings because the latest generation of LLMs is able to build a bot in minutes, enabling reduction of headcount previously devoted to bot-building. Additionally, we have moved to a product-led growth structure where we flattened the organization to align to more efficient sales and service support ratios. In connection with the restructuring initiatives, the Company recognized restructuring costs of $3.3 million and $11.5 million during the three months ended March 31, 2024 and 2023, respectively, which is included in restructuring costs in the accompanying condensed consolidated statements of operations. Such costs primarily include severance and other compensation costs as well as IT infrastructure contract termination costs.

The following table presents the detail of the liability for the Company’s restructuring charges, which is included within accrued expenses and other current liabilities within the accompanying condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023:


	March 31, 2024		December 31, 2023
	(In thousands)
Balance, beginning of the year	$	2,076	$	803

IT contract termination costs	715		5,744
Severance and other compensation associated costs	2,594		16,920
Cash payments	(3,577)		(21,391)
Balance, end of period	$	1,808	$	2,076

The Company anticipates that payments associated with the employee severance and other compensation associated costs reflected in the table above will be substantially completed by December 31, 2024.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table presents the detail of expenses for the Company’s restructuring charges for the three months ended March 31, 2024 and 2023:


	Three Months Ended
	March 31,
	2024		2023
	(In thousands)
Lease restructuring costs	$	—	$	1
IT contract termination costs	715		—
Severance and other associated costs	2,594		11,514
Total restructuring costs	$	3,309	$	11,515

Note 14. Legal Matters

Stockholder Litigation

In December 2023, a putative stockholder class action entitled Damri v. LivePerson, Inc., No. 1:23-cv-10517, was filed under the federal securities laws against the Company, its former Chief Executive Officer, and its Chief Financial Officer in the United States District Court for the Southern District of New York. The complaint alleges that the Company’s Form 10-Q filings and forecasts for the first, second, and third quarters of fiscal year 2022 were false and misleading in violation of Section 10(b) of the Securities Exchange Act of 1934, based on the Company’s later disclosures and report on Form 10-K on March 16, 2023. A parallel litigation on behalf of stockholders who purchased their shares on the Tel Aviv Stock Exchange, entitled Weissbrod v. LivePerson, Inc., is pending in the Tel Aviv District Court in Israel, but has been stayed pending further developments in the Damri case.

In January 2024, a purported derivative action entitled Marti v. LoCascio, No. 1:24-cv-00598, was filed in the United States District Court for the Southern District of New York by a purported stockholder of the Company against the Company’s former Chief Executive Officer, its Chief Financial Officer, most of the members of the current board of directors and several former directors. The derivative litigation claims that the Company itself was harmed by the same acts and omissions underlying the Damri federal securities lawsuit, and seeks to recover unspecified losses on behalf of the Company. The Marti case is stayed pending further developments in the Damri case.

In January 2024, a purported stockholder of the Company filed a lawsuit against the Company and its Board of Directors entitled Browne v. Layfield, No. 2024-0079, in the Court of Chancery of the State of Delaware. The complaint asserted a claim for breach of fiduciary duty based upon a Tax Benefits Preservation Plan. In February 2024, the Board approved technical amendments to the Tax Benefits Preservation Plan which were filed by the Company on Form 8-K, and the case was dismissed as moot, subject to attorneys’ fees on behalf of the plaintiff.

In February 2024, Starboard Value LP and several of its related entities and investment funds filed a lawsuit against the Company, its former Chief Executive Officer and its Chief Financial Officer entitled Starboard Value LP v. LivePerson, Inc., No. 2024-0103, in the Court of Chancery of the State of Delaware. The complaint alleges common law fraud, fraudulent inducement and negligent misrepresentation in connection with an alleged scheme to induce Starboard to settle its 2022 proxy contest against the Company and, as stated in the complaint, involves previous Starboard allegations of misrepresentations in the Company's public disclosures that the Company previously informed Starboard were found to be unsubstantiated following an independent investigation. The complaint seeks unspecified damages. The defendants have filed an answer denying the substantive allegations of the compliant.

COVID-Related Matters

As has been widely reported, there is heightened scrutiny by the federal government across many programs related to global novel coronavirus disease (“COVID-19”) that were introduced during the COVID-19 pandemic. The Company previously provided products and services related to COVID-19 testing and accompanying software. Those products and

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

services have been the subject of inquiry and review by Medicare, the Department of Justice and the U.S. Food and Drug Administration.

The Company has discontinued all products and services related to COVID-19, and has responded to and intends to continue to cooperate with governmental inquiries related to its previous engagement in COVID-19 related product and service offerings.

Other Legal, Administrative, Governmental and Regulatory Matters

From time to time, the Company is or may be subject to or involved in legal, administrative, governmental and/or regulatory proceedings, inquiries and investigations as well as actual or threatened litigation, claims and/or demands (each an “Action” and collectively “Actions”). These have included and may include (without limitation) Actions brought by or against the Company, its affiliates, subsidiaries, directors and/or officers with respect to intellectual property, contracts, financial, commercial, employment, legal, compliance, privacy, data security, regulatory and/or other matters related to our business, as well as Actions brought against the Company’s customers for which the Company has a contractual indemnification obligation.

Regardless of the outcome, Actions can have an adverse impact on the Company because of defense and/or settlement costs, diversion of management resources, reputational risks and other factors.

Accruals

The Company accrues for certain contingencies when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated and discloses certain contingencies for which no accrual has been made as appropriate and in compliance with ASC 450, “Contingencies”. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. The accruals or estimates, if any, resulting from the foregoing analysis, are reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular matter.

Note 15. Income Taxes

Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are expected to become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

The Company includes interest accrued on the underpayment of income taxes and certain interest expense and penalties, if any, related to unrecognized tax benefits as a component of the income tax provision. The Company maintains a valuation allowance against its U.S., e-bot7 Germany and Bulgaria deferred tax assets as it considered its cumulative losses in recent years as a significant piece of negative evidence. Since valuation allowances are evaluated by jurisdiction, the Company believes that the deferred tax assets related to LivePerson Australia Pty. Ltd., Engage Pty. Ltd., LivePerson (UK) Ltd., LivePerson Japan, and LivePerson Ltd. (Israel) are more likely than not to be realized as these jurisdictions have positive cumulative pre-tax book income after adjusting for permanent and one-time items. During the year ended December 31, 2023, there was an increase in the valuation allowance recorded of $23.7 million.

For the three months ended March 31, 2024, the Company recorded a tax provision of $0.4 million. This entire amount consists of a tax provision on operating earnings of non-US subsidiaries and interest accrual on unrecognized tax benefits in Israel.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company had a valuation allowance on certain deferred tax assets for the year ended December 31, 2023 of $211.2 million. Inherent in the Company’s 2024 annual effective tax rate is an estimated increase in the valuation allowance of $24.9 million, all of which would be recorded as an expense. During 2023, an increase in the valuation allowance in the amount of $23.7 million was recorded as an expense.

Note 16. Equity Method Investment

On February 13, 2022, the Company and Pasaca Capital Inc. (“Pasaca”) entered into a joint venture agreement (the “JV Agreement”) to form Claire Holdings, Inc. (“Claire”), a joint venture to build, create, and administer a marketplace for health and well-being diagnostic testing. Pursuant to the terms of the JV Agreement, the Company agreed to contribute a total of $19.0 million over a five-year period in exchange for a 19.2% ownership interest in Claire. Pasaca agreed to contribute $80.0 million to Claire over a five-year period in exchange for an 80.8% ownership interest in Claire. The Company accounts for its 19.2% interest in Claire using the equity method of accounting. The Company recorded its ownership percentage of losses of Claire in Other income (expense), net in the amount of $0.6 million for the three months ended March 31, 2023. The Company’s equity method investment in joint venture was reduced to zero during the prior year, based on the prior year losses, and remained at zero on the condensed consolidated balance sheet as of March 31, 2024. Refer to Note 18 – Related Parties for additional information.

Note 17. Variable Interest Entities

The Company prepares its condensed consolidated financial statements in accordance with ASC 810, “Consolidation”, which provides for the consolidation of variable interest entities (“VIEs”) of which the Company is the primary beneficiary.

In February 2022, the Company acquired WildHealth as well as certain variable interests that WildHealth has in four Professional Corporations (“PCs”). The PCs are owned by a medical practitioner in accordance with certain state laws which restrict the corporate practice of medicine and require medical practitioners to own such entities. WildHealth provides management and other services to the PCs in exchange for a management fee and provides financial support to the PCs through a revolving credit arrangement. WildHealth also has separate agreements with the equity holder of the PCs where it may acquire and assign such equity interests for certain PCs. The agreement entitles WildHealth to control rights sufficient to require the Company to consolidate the balance sheet and results of operations of the PCs as VIEs. The Company determined that the PCs are VIEs as WildHealth is the primary beneficiary of the PCs.

The assets, liabilities, revenues, and operating results of the VIEs after elimination of intercompany transactions were not material as of and for the three months ended March 31, 2024.

Note 18. Related Parties

Related parties are defined as entities related to the Company’s directors or main shareholders as well as equity method affiliates. During the year ended December 31, 2023, the Company provided services to Claire, an equity method affiliate (refer to Note 16 – Equity Method Investment for additional information on the equity method affiliate) in exchange for fees through certain commercial arrangements. These arrangements facilitated Claire’s build out and operations.

In connection with the JV Agreement, the Company entered into commercial agreements with Claire, under which the Company agreed to provide custom software development and managed services in exchange for fees governed by the terms and conditions set forth therein. In accordance with guidance under ASC 606, Claire is considered a customer of the Company. No revenues were recognized for the services provided to Claire included in the Company’s condensed consolidated statements of operations for the three months ended March 31, 2024, compared to revenues of $3.8 million for the three months ended March 31, 2023. As of March 31, 2024, the Company has accounts receivable of $2.1 million included in the Company’s condensed consolidated balance sheet, which is fully recognized in its allowance for credit losses. Total accounts receivable of $2.1 million as of December 31, 2023 was included in the Company’s condensed consolidated balance sheet, for which the Company recognized $1.5 million in its allowance for credit losses.

Note 19. Divestiture

Fiscal 2023 Divestitures

In the fourth quarter of 2022, the Company entered into a non-binding Letter of Intent to divest Kasamba, Inc. and Kasamba LTD (together “Kasamba”), which represented the Company’s Consumer segment. Pursuant to ASC Subtopic 360-10, “Impairment or Disposal of Long-Lived Assets”, the Company applied held for sale accounting treatment to the assets and liabilities of Kasamba. Accordingly, the related net assets were separately presented in current assets and current liabilities as held for sale on the consolidated balance sheets as of December 31, 2022, up until the close of the transaction. The held for sale classification also resulted in ceasing depreciation and amortization on the designated assets.

The Share Purchase Agreement between Ingenio, LLC (“Ingenio”) and the Company closed on March 20, 2023. In accordance with the Share Purchase Agreement, the Company sold all of the issued and outstanding shares of Kasamba for $16.9 million which was received in cash upon closing; and $2.6 million deferred payment to be received within a year of the close transaction date, which was included in prepaid expenses and other current assets on the Company’s condensed consolidated balance sheets as of March 31, 2023. $11.8 million was required to be held in various escrow accounts for up to 15 months, and was included in restricted cash on the Company’s consolidated balance sheets; however, $9.8 million of this escrow amount was released as of December 31, 2023. The transaction resulted in a gain of $17.6 million, which was recognized and presented separately as a gain on divestiture on the Company’s consolidated statements of operations during the year ended December 31, 2023. During the three months ended March 31, 2024, the Company recognized a post-closing adjustment pertaining to the final agreement in the amount of $1.8 million, which is recorded in General and administrative expenses in the condensed consolidated statement of operations.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion of our financial condition and results of operations in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report, particularly in “Risk Factors.”

Key Metrics

Average Annual Revenue Per Enterprise and Mid-market Customer (“ARPC”) and revenue retention are currently the key performance metrics our management uses to assess the health and trajectory of the Company. These metrics should be viewed independently of revenue, deferred revenue and remaining performance obligations. ARPC increased to approximately $625,000 for the trailing twelve months ended March 31, 2024, as compared to approximately $560,000 for the trailing twelve months ended March 31, 2023. Revenue retention for our enterprise and mid-market customers on the Conversational Cloud, which represents the trailing twelve month change in total revenue from existing customers after upsells, downsells and attrition, was approximately 89% in the first quarter of 2024, below our target range of 105% to 115% and below the comparable period in 2023.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (“GAAP”). As such, we are required to make certain estimates, judgments and assumptions that management believes are reasonable based upon the information available. We base these estimates on our historical experience, future expectations and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for our judgments that may not be readily apparent from other sources.

There have been no significant changes in our critical accounting policies and estimates during the three months ended March 31, 2024, as compared to the critical accounting policies and estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 4, 2024.

Recently Issued Accounting Standards

See Note 1 – Description of Business and Basis of Presentation under Item 1 of this Quarterly Report on Form 10-Q for additional information about recent accounting guidance not yet adopted and recently adopted accounting pronouncements.

Results of Operations

We enable brands to leverage the Conversational Cloud’s sophisticated intelligence engine to connect with consumers through an integrated suite of mobile and online business messaging technologies. The Conversational Cloud enables businesses to have conversations with millions of consumers as personally as they would with one consumer.

Comparison of the Three Months Ended March 31, 2024 and March 31, 2023

Revenue

The following tables set forth our results of operations for the periods presented and as a percentage of our revenues for those periods. The period-to-period comparison of financial results is not necessarily indicative of future results.


	Three Months Ended March 31,
	2024		2023		% Change

	(Dollar in thousands)
Revenue	$	85,149	$	107,661	(21)	%

Revenue decreased by 21% to $85.1 million for the three months ended March 31, 2024 from $107.7 million for the comparable period in 2023. This decrease in revenue is driven primarily by decreases in hosted services of $15.8 million and professional services of approximately $6.7 million. Included in hosted services is a decrease in revenue that is variable based on interactions and usage of approximately $4.5 million for the three months ended March 31, 2024. Further, on March 20, 2023, the Company completed the sale of Kasamba and therefore ceased recognizing revenue related to Kasamba effective on the transaction close date. This sale eliminated the entire Consumer segment, as a result of which revenue is presented within a single consolidated segment. Hosted services for Consumer included $7.1 million for the three months ended March 31, 2023 relating to Kasamba.

Cost of Revenue

Cost of revenue consists of compensation costs relating to employees who provide customer service to our customers, compensation costs relating to our network support staff, outside labor provider costs, the cost of supporting our server and network infrastructure, and allocated occupancy costs and related overhead.


	Three Months Ended March 31,
	2024			2023			% Change

	(Dollar in thousands)
Cost of revenue	$	29,463		$	43,096		(32)	%
Percentage of total revenue	35		%	40		%
Headcount (at period end)	229			226			1	%

Cost of revenue decreased by 32% to $29.5 million for the three months ended March 31, 2024, from $43.1 million for the comparable period in 2023. This decrease in expense is primarily attributable to a decrease in outsourced labor and related costs of approximately $6.6 million, a decrease in salary and employee-related expenses due to attrition from prior period of approximately $3.9 million, a decrease in compensation expense of $1.7 million, a decrease in amortization expenses of approximately $1.8 million related to purchased intangible assets associated with prior period acquisitions and finance leases settled during the three months ended March 31, 2024. These decreases were partially offset by an increase in software, hosting and other expenses of approximately $0.5 million.

Sales and Marketing

Sales and marketing expenses consist of compensation and related expenses for sales and marketing personnel, as well as advertising, marketing events, public relations, trade show exhibit expenses and allocated occupancy costs and related overhead.


	Three Months Ended March 31,
	2024			2023			% Change

	(Dollar in thousands)
Sales and marketing	$	30,130		$	34,470		(13)	%
Percentage of total revenue	35		%	32		%
Headcount (at period end)	287			405			(29)	%

Sales and marketing expenses decreased by 13% to $30.1 million for the three months ended March 31, 2024 from $34.5 million for the comparable period in 2023. This decrease was primarily attributable to a decrease in marketing expense of approximately $4.3 million, a decrease in salary and employee-related expenses of approximately $0.7 million, and a decrease in software and hosting expenses of approximately $0.6 million, partially offset by an increase in business services and outsourced subcontracted labor of approximately $1.1 million.

General and Administrative

Our general and administrative expenses consist of compensation and related expenses for executive, accounting, legal, human resources and administrative personnel, professional fees and other general corporate expenses.


	Three Months Ended March 31,
	2024			2023			% Change

	(Dollar in thousands)
General and administrative	$	21,752		$	31,447		(31)	%
Percentage of total revenue	26		%	29		%
Headcount (at period end)	143			149			(4)	%

General and administrative expenses decreased by 31% to $21.8 million for the three months ended March 31, 2024 from $31.4 million for the comparable period in 2023. This decrease is primarily attributable to a decrease in other expenses of approximately $5.5 million related to legal fees, a decrease in salary and employee-related expenses of approximately $2.5 million from restructuring activities, and a decrease in business services and outsourced subcontracted labor of approximately $3.3 million. These decreases were partially offset by a divestiture-related working capital adjustment of approximately $1.8 million for the three months ended March 31, 2024.

Product Development

Our product development expenses consist of compensation and related expenses for product development personnel as well as allocated occupancy costs and related overhead and outsourced labor and expenses for testing new versions of our software.


	Three Months Ended March 31,
	2024			2023			% Change

	(Dollar in thousands)
Product development	$	30,120		$	36,519		(18)	%
Percentage of total revenue	35		%	34		%
Headcount (at period end)	468			452			4	%

Product development costs decreased by 18% to $30.1 million for the three months ended March 31, 2024 from $36.5 million for the comparable period in 2023. This decrease is primarily related to a decrease in salaries and employee-related

expenses of approximately $4.9 million and a decrease in business services and outsourcing subcontracted labor of approximately $2.6 million, partially offset by an increase in depreciation of approximately $1.3 million.

We continue to invest in new product development efforts to expand the capability of the Conversational Cloud. Upon completion, the project costs will be depreciated over five years. For the three months ended March 31, 2024, $5.7 million was capitalized for software development costs, compared to $8.1 million for the comparable period in 2023.

Restructuring Costs

Restructuring costs consist of reprioritizing and reallocating resources to focus on areas believed to show high growth potential.


	Three Months Ended March 31,
	2024			2023			% Change

	(Dollar in thousands)
Restructuring costs	$	3,309		$	11,515		(71)	%
Percentage of total revenue	4		%	11		%

Restructuring costs decreased by 71% to $3.3 million during the three months ended March 31, 2024 from $11.5 million for the comparable period in 2023. Restructuring costs decreased due to incremental reductions in costs related to the restructuring initiative that commenced during the second quarter of 2022, primarily consisting of severance and other associated costs related to the reduction in our workforce. Severance and other related compensation costs decreased by $8.9 million, partially offset by an increase of $0.7 million of IT infrastructure contract termination costs for the three months ended March 31, 2024 compared to March 31, 2023. We began a restructuring initiative to realign our cost structure to better reflect significant product and business model innovation and have had changes since then due to acquisitions and various other factors outside our control. In the first quarter of 2023, due to the changing technology landscape related to the evolution of LLMs, we identified opportunities for significant cost savings because the latest generation of LLMs is able to build a bot in minutes, enabling reduction of headcount previously devoted to bot-building. Additionally, we have moved to a product-led growth structure where we flattened the organization to align to more efficient sales and service support ratios. Refer to Note 13 – Restructuring for additional information about the restructuring initiative.

Impairment of Goodwill


	Three Months Ended March 31,
	2024			2023			% Change

	(Dollar in thousands)
Impairment of goodwill	$	3,627		$	—		100%
Percentage of total revenue	4		%	—		%

Goodwill impairment was approximately $3.6 million during the three months ended March 31, 2024. This non-cash charge was a result of an interim goodwill impairment test and was attributable to the WildHealth reporting unit. There were no impairment charges for the three months ended March 31, 2023.

Impairment of Intangibles and Other Assets


	Three Months Ended March 31,
	2024			2023			% Change

	(Dollar in thousands)
Impairment of intangibles and other assets	$	2,221		$	—		100	%
Percentage of total revenue	3		%	—		%

Impairment of intangibles and other assets was approximately $2.2 million during the three months ended March 31, 2024. This non-cash charge was a result of our impairment test in the first quarter of 2024 and was attributable to our intangible assets associated with our WildHealth reporting unit. There were no impairments of intangible assets during the three months ended March 31, 2023.

Total other income, net

Total other income (expense), net consists primarily of fair value adjustments for earn-outs, foreign currency gains and losses and income (loss) from our equity method investment. Interest income, net includes interest income from cash deposits, amortization of debt discount, amortization of issuance costs, and interest expense from our convertible senior notes.


	Three Months Ended March 31,
	2024		2023		% Change

	(Dollar in thousands)
Interest income, net	$	1,332	$	1,801	(26)	%
Other (expense) income, net	(237)		14,662		(102)	%
Total other income, net	$	1,095	$	16,463	(93)	%

Total other income, net decreased by 93% to $1.1 million for the three months ended March 31, 2024 from $16.5 million for the comparable period in 2023. The decrease is primarily attributable to the Company’s prior year gain of $10.0 million related to a legal settlement and a gain of $7.2 million resulting from the repurchase of 2024 Notes during the three months ended March 31, 2023. The remaining amount of total other income, net fluctuation is attributable to the prior write down of all accounts receivable from the Company’s equity method investment and currency rate fluctuations compared to the three months ended March 31, 2023.

Provision for income taxes


	Three Months Ended March 31,
	2024		2023		% Change

	(Dollar in thousands)
Provision for income taxes	$	362	$	1,214	(70)	%

Provision for income taxes was $0.4 million and $1.2 million for the three months ended March 31, 2024 and 2023, respectively. Our consolidated effective tax rate during the three months ended March 31, 2024 was impacted by the statutory income tax rates applicable to each of the jurisdictions in which we operate, valuation allowance recorded against losses generated in the U.S. and Germany and changes to unrecognized tax benefits in Israel. The decrease in the tax provision in the current period as compared to the prior period is due to changes in the forecasted earnings by jurisdiction year over year and a provision related to an increase in valuation allowance on deferred tax assets resulting from a release of deferred tax liabilities related to the sale of Kasamba, Inc. that existed in the prior period.

Liquidity and Capital Resources


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Condensed Consolidated Statements of Cash Flows Data:
Net cash provided by (used in) operating activities	$	1,099	$	(5,918)
Net cash (used in) provided by investing activities	(12,710)		2,839
Net cash used in financing activities	$	(72,697)	$	(149,806)

As of March 31, 2024, we had approximately $129.0 million in cash, cash equivalents, and restricted cash, a decrease of approximately $83.9 million from December 31, 2023. The decrease is primarily attributable to the Company’s repayment in full at maturity of the outstanding $72.5 million in aggregate principal amount of the 2024 Notes, coupled with various other uses of cash for operating purposes.

Net cash provided by operating activities was $1.1 million for the three months ended March 31, 2024. Our net loss of $35.6 million includes the effect of non-cash expenses related to depreciation of $8.2 million, a net expense in stock-based compensation of $7.6 million, amortization of purchased intangible assets and finance leases of $4.2 million, allowance for credit losses of $4.7 million, a goodwill impairment of $3.6 million and intangible and other assets impairment of $2.2 million. This was further driven by a decrease in accrued expenses and other current liabilities of $17.0 million, an increase in contract acquisition costs of $2.4 million, partially offset by a decrease in accounts receivable of $5.4 million, a decrease in prepaid expenses and other current assets of $5.9 million, an increase in other liabilities of $0.9 million, an increase in accounts payable of $2.0 million, and an increase in deferred revenue of $10.9 million.

Our net loss of $17.4 million for the three months ended March 31, 2023 includes the effect of non-cash expenses related to stock-based compensation of $11.3 million, depreciation of $7.4 million, amortization of purchased intangible assets and finance leases of $5.4 million partially offset by a gain on divestiture of $17.6 million. This was further driven by an increase in accounts receivable of $34.7 million, an increase in prepaid expenses and other current assets of $6.3 million, a decrease in other liabilities of $5.9 million, a decrease in accounts payable of $9.9 million, partially offset by an increase in accrued expenses and other current liabilities of $41.3 million and an increase in deferred revenue of $24.8 million.

Net cash used in investing activities was $12.7 million for the three months ended March 31, 2024, and was primarily driven by purchases of property and equipment and capitalization of internally developed software. Net cash provided by investing activities was $2.8 million for the three months ended March 31, 2023 and was primarily driven by the proceeds from the sale of Kasamba, offset by purchases of property and equipment and capitalization of internally developed software.

Net cash used in financing activities was $72.7 million for the three months ended March 31, 2024, which was driven primarily by the full repayment of our 2024 Notes. Net cash used in financing activities was $150.4 million for the three months ended March 31, 2023, which was driven primarily by the repurchase of our 2024 convertible notes.

We have incurred significant expenses to develop our technology and services, to hire employees in our customer service and sales and marketing departments, and for the amortization of purchased intangible assets, as well as non-cash compensation costs. Historically, we have incurred net losses and negative cash flows for various quarterly and annual periods since our inception, including during numerous quarters and annual periods in the past several years. As of March 31, 2024, we had an accumulated deficit of approximately $892.6 million.

Our principal sources of liquidity are the net proceeds from the issuance of our convertible senior notes, after deducting purchaser discounts and debt issuance costs paid by us, and payments received from customers using our products. We anticipate that our current cash and cash equivalents will be sufficient to satisfy our working capital and capital requirements for at least the next 12 months. However, we cannot assure you that we will not require additional funds prior to such time, and we would then seek to sell additional equity or debt securities through public financings, or seek alternative sources of financing. Further, we plan to refinance the 2026 Notes on or prior to their maturity, and we are currently reviewing our capital structure with a goal of refinancing the 2026 Notes. We cannot assure you that additional funding will be available on favorable terms, when needed, if at all. If we are unable to obtain any necessary financing, we may be required to further reduce the scope of our planned sales and marketing and product development efforts, which could materially adversely affect our financial condition and operating results. In addition, we may require additional funds in order to fund more rapid expansion, to develop new or enhanced services or products or to invest in or acquire complementary businesses, technologies, services or products.

The Company may from time to time, subject to board authorization and any applicable restrictions under contracts to which it may be or become a party, depending upon market conditions and the Company’s financing needs, use available funds to refinance or repurchase its outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise, in compliance with applicable laws, rules and regulations, at prices and on terms the Company deems appropriate (which, in the case of debt securities, may be below par) and subject to the Company’s cash requirements for other purposes and other factors management deems relevant.

We do not engage in off-balance sheet financing arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Foreign Currency Exchange Risks

We actively monitor the movement of the U.S. dollar against the NIS, Pound Sterling, Euro, Australian dollar, and Japanese Yen and have considered the use of financial instruments, including but not limited to derivative financial instruments, which could mitigate such risk. If we determine that our risk of exposure materially exceeds the potential cost of derivative financial instruments, we may in the future enter into these types of arrangements. Our Israeli operations have currency rate fluctuation risk associated with the exchange rate movement of the U.S. dollar against the NIS. During the three months ended March 31, 2024, the U.S. dollar appreciated by approximately 1% as compared to the NIS. During the three months ended March 31, 2024, expenses generated by our Israeli operations totaled approximately $3.6 million. Based on our exposure to NIS exchange rate fluctuation against a dollar as of March 31, 2024, an increase or decrease in the value of the NIS would not have a material impact on our income before income taxes.

Collection Risks

Our accounts receivable are subject, in the normal course of business, to collection risks. We regularly assess these risks and have established policies and business practices to protect against the adverse effects of collection risks. During the three months ended March 31, 2024, our allowance for credit losses decreased by $0.1 million to approximately $9.2 million. During the three months ended March 31, 2023, we decreased our allowance for credit losses by $0.1 million to approximately $9.1 million. A large proportion of our receivables are due from larger corporate customers that typically have longer payment cycles. We base our allowance for credit losses on specifically identified credit risks of customers, historical trends and other information that we believe to be reasonable. Receivables are written-off and charged against the applicable recorded allowance when we have exhausted collection efforts without success. We adjust our allowance for credit losses when accounts previously reserved have been collected.

An allowance for credit losses is established for losses expected to be incurred on accounts receivable balances. Judgment is required in the estimation of the allowance and we evaluate the collectability of our accounts receivable and contract assets based on a combination of factors. If we become aware of a customer’s inability to meet its financial obligations, a specific allowance is recorded to reduce the net receivable to the amount reasonably believed to be collectible from the customer. For all other customers, we use an aging schedule and recognize allowances for credit losses based on the creditworthiness of the debtor, the age and status of outstanding receivables, the current business environment and our historical collection experience adjusted for current expectations for the customer or industry. Accounts receivable are written off against the allowance for uncollectible accounts when we determine amounts are no longer collectible.

Interest Rate Risk

Our investments consist of cash and cash equivalents. Therefore, changes in market interest rates do not affect in any material respect the value of the investments as recorded by us.

Inflation Risk

We do not believe that inflation has had a material effect on our business, financial conditions or results of operations. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, including the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our “disclosure controls and procedures,” as that term is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of March 31, 2024. Disclosure controls and procedures ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed and summarized within the time periods specified in the Securities and Exchange Commission’s rules and forms, and ensure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2024.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the quarter ended March 31, 2024 identified in connection with the evaluation thereof by our management, including the Chief Executive Officer and Chief Financial Officer, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Limitations of the Effectiveness of Internal Control

A control system, no matter how well conceived and operated, can only provide reasonable, not absolute, assurance that the objectives of the internal control system are met. Because of the inherent limitations of any internal control system, no evaluation of controls can provide absolute assurance that all control issues, if any, have been detected.

Part II. Other Information

Item 1. Legal Proceedings

The information called for by this Item is incorporated herein by reference to Note 14 – Legal Matters, in the Notes to the Unaudited Condensed Consolidated Financial Statements.

Item 1A. Risk Factors

Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, filed on March 4, 2024, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. Other than as set forth below, there have been no material changes to the risk factors described in our most recent Annual Report on Form 10-K.

Our failure to regain compliance with the continued listing requirements of the Nasdaq Global Select Market could result in a delisting of our common stock.

Our common stock currently is listed on the Nasdaq Global Select Market. We are required to meet specified financial requirements in order to maintain such listing, including a closing bid price of at least $1.00.

On May 10, 2024 we received a notification from Nasdaq stating that the closing bid price of our common stock has been less than $1.00 for 30 consecutive trading days. We have 180 calendar days from such notification to regain compliance with the minimum closing bid price requirement by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive trading days.

We can provide no assurance that we will be able to regain our compliance with the listing requirements or that any actions taken by us in an effort to restore our compliance would allow our common stock to remain listed, stabilize the market price of our common stock, improve the liquidity of our common stock, prevent our common stock from again dropping below

the minimum bid price requirement, or prevent future non-compliance with the listing requirements. In addition, to maintain a listing on Nasdaq, we must satisfy minimum financial and other continued listing requirements and standards, including those regarding minimum stockholders’ equity, and certain corporate governance requirements. If we are unable to satisfy these requirements or standards, we could be subject to delisting, which would have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. Further, the failure of our common stock to be listed or quoted on any of The Nasdaq Global Select Market, The Nasdaq Global Market or The New York Stock Exchange would constitute a “fundamental change” under the indenture governing the 2026 Notes.

If our common stock is delisted from Nasdaq, it is unlikely that our common stock would qualify for listing on another national securities exchange in the United States, and trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQX, the OTCQB or the Pink Market maintained by OTC Markets Group Inc. We cannot assure you that our common stock, if delisted from Nasdaq, will ever be listed on another securities exchange or quoted on an over-the-counter quotation system. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. Accordingly, delisting from Nasdaq could make trading our common stock more difficult for investors, likely leading to declines in our share price, trading volume and liquidity. Delisting from Nasdaq could also result in negative publicity and make it more difficult for us to raise additional capital. The absence of such a listing may adversely affect the acceptance of our common stock as transaction consideration or the value accorded our common stock by other parties. Further, if we are delisted, we would also incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our stockholders to sell our common stock in the secondary market.

If our common stock is delisted, it may come within the definition of “penny stock” as defined in the Exchange Act and would be covered by Rule 15g-9 of the Exchange Act. This rule imposes additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors which may further limit the market liquidity of our common stock and the ability of our stockholders to sell our common stock in the secondary market. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

There were no unregistered sales of equity securities by the issuer during the three months ended March 31, 2024.

Purchase of Equity Securities by the Issuer

There were no repurchases of equity securities by the issuer during the three months ended March 31, 2024.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

(a) None.

(b) None.

(c) During the three months ended March 31, 2024, no director or executive officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulations S-K, except as described in the table below.

Trading Arrangement

Director/
Officer Name

Title

Date of Adoption/Termination

Rule 10b5-1

Trading Arrangement End Date

Aggregate Number of Securities to be Purchased or Sold

Bruce Hansen

Director

3/12/2024

Yes

3/06/2025

34,045

upon vesting of RSUs.

Alex Kroman

Chief Product & Technology Officer

3/12/2024

Yes

3/07/2025

185,875

upon vesting of RSUs and performance share awards.

ITEM 6. EXHIBITS



3.1		Certificate of Designations of the Series A Junior Participating Preferred Stock of the Company, dated January 22, 2024 (incorporated by reference to Exhibit 3.1 to LivePerson’s Current Report on Form 8-K filed on January 22, 2024)

4.1		Tax Benefits Preservation Plan, dated as of January 22, 2024, by and between the Company and Equiniti Trust Company, LLC as rights agent (which includes the Form of Rights Certificate as Exhibit B thereto) (incorporated by reference to Exhibit 4.1 to LivePerson’s Current Form 8-K filed on January 22, 2024)

4.2		Amendment, dated as of February 16, 2024, to the Tax Benefits Preservation Plan, between LivePerson, Inc. and Equiniti Trust Company, LLC (incorporated by reference to Exhibit 4.1 to LivePerson’s Current Form 8-K filed on February 16, 2024)

10.1		Amendment to LivePerson, Inc. 2018 Inducement Plan (as amended through February 9, 2022) (incorporated by reference to Exhibit 99.2 to LivePerson’s Registration Statement on Form S-8 filed on March, 8, 2024)

10.2		Separation and Release of Claims Agreement, dated January 3 1, 2024, between LivePerson, Inc. and Robert LoCascio (inc orporated by reference to Exhibit 10.29 to LivePerson ’s Form 10-K/A filed on April 29, 2024)

31.1	*	Certification by principal executive officer pursuant to Exchange Act Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2	*	Certification by principal financial officer pursuant to Exchange Act Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1	**	Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2	**	Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS	*	Inline XBRL Instance Document -- The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH	*	Inline XBRL Taxonomy Extension Schema Document

101.CAL	*	Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF	*	Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB	*	Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE	*	Inline XBRL Taxonomy Extension Presentation Linkbase Document

104	*	Cover Page Interactive Data File (formatted as Inline XBRL)

* Filed herewith

** Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		LIVEPERSON, INC.
		(Registrant)

Date:	May 10, 2024	By:	/s/ JOHN SABINO
		Name:	John Sabino

		Title:	Chief Executive Officer
			(Principal Executive Officer)

Exhibit 31.1

CERTIFICATIONS

I, John Sabino, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of LivePerson, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date:	May 10, 2024	By:	/s/ John Sabino
		Name:	John Sabino
		Title:	Chief Executive Officer (Principal Executive Officer)

Exhibit 31.2

CERTIFICATIONS

I, John Collins, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of LivePerson, Inc.;

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date:	May 10, 2024	By:	/s/ John Collins
		Name:	John Collins
		Title:	Chief Financial Officer and Chief Operating Officer (Principal Financial Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, John Sabino, Chief Executive Officer of LivePerson, Inc. (the “Company”), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)the Quarterly Report of the Company on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:	May 10, 2024	By:	/s/ John Sabino
		Name:	John Sabino
		Title:	Chief Executive Officer (Principal Executive Officer)

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent the Company specifically incorporates it by reference.

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, John Collins, Chief Financial Officer of LivePerson, Inc. (the “Company”), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:	May 10, 2024	By:	/s/ John Collins
		Name:	John Collins
		Title:	Chief Financial Officer and Chief Operating Officer (Principal Financial Officer)

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	May 06, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	000-30141
Entity Registrant Name	LIVEPERSON, INC.
Entity Central Index Key	0001102993
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3861628
Entity Address, Address Line One	530 7th Ave, Floor M1
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10018
City Area Code	(212)
Local Phone Number	609-4200
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		88,614,097
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	LPSN
Security Exchange Name	NASDAQ
Rights to Purchase Series A Junior Participating Preferred Stock
Document Information [Line Items]
No Trading Symbol Flag	true
Title of 12(b) Security	Rights to Purchase Series A JuniorParticipating Preferred Stock
Security Exchange Name	NASDAQ
No Trading Symbol Flag	true

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 127,057	$ 210,782
Restricted cash	1,960	2,143
Accounts receivable, net of allowance for credit losses of $9,235 and $9,290 as of March 31, 2024 and December 31, 2023, respectively	71,365	81,802
Prepaid expenses and other current assets (Note 1)	20,954	26,981
Total current assets	221,336	321,708
Operating lease right-of-use assets (Note 9)	3,431	4,135
Property and equipment, net (Note 6)	117,893	119,325
Contract acquisition costs, net	39,326	37,354
Intangible assets, net (Note 5)	56,009	61,625
Goodwill (Note 5)	280,956	285,631
Deferred tax assets	4,473	4,527
Other assets	1,264	1,208
Total assets	724,688	835,513
Current liabilities:
Accounts payable	14,528	13,555
Accrued expenses and other current liabilities (Note 7)	75,506	97,024
Deferred revenue (Note 2)	92,414	81,858
Convertible senior notes (Note 8)	0	72,393
Operating lease liabilities (Note 9)	2,632	2,719
Total current liabilities	185,080	267,549
Convertible senior notes, net of current portion (Note 8)	512,076	511,565
Operating lease liabilities, net of current portion (Note 9)	1,466	2,173
Deferred tax liabilities	3,002	2,930
Other liabilities	3,881	3,158
Total liabilities	705,505	787,375
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value - 5,000,000 shares authorized, none issued	0	0
Common stock, $0.001 par value - 200,000,000 shares authorized, 91,131,823 and 90,603,519 shares issued, 88,365,750 and 87,837,446 shares outstanding as of March 31, 2024 and December 31, 2023, respectively.	92	91
Treasury stock - 2,766,073 shares at March 31, 2024 and December 31, 2023	(3)	(3)
Additional paid-in capital	921,895	913,522
Accumulated deficit	(892,619)	(856,988)
Accumulated other comprehensive loss	(10,182)	(8,484)
Total stockholders’ equity	19,183	48,138
Total liabilities and stockholders’ equity	$ 724,688	$ 835,513

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) $ in Thousands	Mar. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Statement of Financial Position [Abstract]
Accounts receivable, allowances including credit loss and sales reserve \| $	$ 9,235	$ 9,290
Preferred stock, par value (in dollars per share) \| $ / shares	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, issued (in shares)	0	0
Common stock, authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	91,131,823	90,603,519
Common stock, outstanding (in shares)	88,365,750	87,837,446
Treasury stock (in shares)	2,766,073	2,766,073

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 85,149,000	$ 107,661,000
Costs, expenses and other:
Cost of revenue	29,463,000	43,096,000
Sales and marketing	30,130,000	34,470,000
General and administrative	21,752,000	31,447,000
Product development	30,120,000	36,519,000
Impairment of goodwill	3,627,000	0
Impairment of intangibles and other assets	2,221,000	0
Restructuring costs	3,309,000	11,515,000
Gain on divestiture	0	(17,591,000)
Amortization of purchased intangible assets	891,000	874,000
Total costs, expenses and other	121,513,000	140,330,000
Loss from operations	(36,364,000)	(32,669,000)
Other income (expense), net:
Interest income, net	1,332,000	1,801,000
Other (expense) income, net	(237,000)	14,662,000
Total other income	1,095,000	16,463,000
Loss before provision for income taxes	(35,269,000)	(16,206,000)
Provision for income taxes	362,000	1,214,000
Net Income (loss)	$ (35,631,000)	$ (17,420,000)
Net loss per share of common stock:
Basic (in dollars per share)	$ (0.40)	$ (0.23)
Diluted (in dollars per share)	$ (0.40)	$ (0.23)
Weighted average shares outstanding:
Basic (in shares)	88,081,654	75,774,812
Diluted (in shares)	88,081,654	75,774,812

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (35,631)	$ (17,420)
Foreign currency translation adjustment	(1,698)	866
Comprehensive loss	$ (37,329)	$ (16,554)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock, Common	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2022		78,350,984	(2,766,073)
Beginning balance at Dec. 31, 2022	$ 68,088	$ 78	$ (3)	$ 771,052	$ (692,362)	$ (10,677)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options (in shares)		18,687
Common stock issued upon exercise of stock options	130			130
Common stock issued upon vesting of restricted stock units (in shares)		413,252
Common stock issued upon vesting of restricted stock units	1	$ 1
Stock-based compensation	9,560			9,560
Common stock issued under Employee Stock Purchase Plan (in shares)		87,794
Common stock issued under Employee Stock Purchase Plan (ESPP)	724			724
Issuance of common stock in connection with acquisitions (Note 9)	380			380
Activity related to divestiture (Note 20)	2,732			66,775	(64,100)	57
Net loss	(17,420)				(17,420)
Other comprehensive income	809					809
Ending balance (in shares) at Mar. 31, 2023		78,870,717	(2,766,073)
Ending balance at Mar. 31, 2023	65,004	$ 79	$ (3)	848,621	(773,882)	(9,811)
Beginning balance (in shares) at Dec. 31, 2023		90,603,519	(2,766,073)
Beginning balance at Dec. 31, 2023	$ 48,138	$ 91	$ (3)	913,522	(856,988)	(8,484)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options (in shares)	0
Common stock issued upon vesting of restricted stock units (in shares)		432,701
Common stock issued upon vesting of restricted stock units	$ 2	$ 1		1
Stock-based compensation	8,251			8,251
Common stock issued under Employee Stock Purchase Plan (in shares)		95,603
Common stock issued under Employee Stock Purchase Plan (ESPP)	121			121
Net loss	(35,631)				(35,631)
Other comprehensive income	(1,698)					(1,698)
Ending balance (in shares) at Mar. 31, 2024		91,131,823	(2,766,073)
Ending balance at Mar. 31, 2024	$ 19,183	$ 92	$ (3)	$ 921,895	$ (892,619)	$ (10,182)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
OPERATING ACTIVITIES:
Net loss	$ (35,631,000)	$ (17,420,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	7,558,000	11,332,000
Depreciation	8,225,000	7,362,000
Reduction of operating lease right-of-use assets	653,000	658,000
Amortization of purchased intangible assets and finance leases	4,217,000	5,435,000
Amortization of debt issuance costs	610,000	920,000
Impairment of goodwill	3,627,000	0	$ 11,895,000
Impairment of intangible assets	2,221,000	0
Change in fair value of contingent consideration	0	(1,709,000)
Gain on repurchase of convertible notes	0	(6,100,000)
Allowance for credit losses	4,722,000	1,079,000	3,319,000
Gain on divestiture	0	(17,591,000)
Deferred income taxes	75,000	589,000
Equity loss in joint venture	0	618,000
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	5,422,000	(34,731,000)
Prepaid expenses and other current assets	5,854,000	(6,262,000)
Contract acquisition costs	(2,370,000)	530,000
Other assets	(75,000)	79,000
Accounts payable	1,966,000	(9,910,000)
Accrued expenses and other current liabilities	(16,976,000)	41,266,000
Deferred revenue	10,852,000	24,750,000
Operating lease liabilities	(738,000)	(944,000)
Other liabilities	887,000	(5,869,000)
Net cash provided by (used in) operating activities	1,099,000	(5,918,000)
INVESTING ACTIVITIES:
Purchases of property and equipment, including capitalized software	(11,501,000)	(9,625,000)
Purchases of intangible assets	(1,209,000)	(1,355,000)
Proceeds from divestiture	0	13,819,000
Net cash (used in) provided by investing activities	(12,710,000)	2,839,000
FINANCING ACTIVITIES:
Principal payments for financing leases	(327,000)	(958,000)
Proceeds from issuance of common stock in connection with the exercise of options and ESPP	122,000	854,000
Payments on repurchase of convertible senior notes	(72,492,000)	(149,702,000)
Net cash used in financing activities	(72,697,000)	(149,806,000)
Effect of foreign exchange rate changes on cash and cash equivalents	400,000	2,849,000
Net decrease in cash, cash equivalents, and restricted cash	(83,908,000)	(150,036,000)
Cash, cash equivalents, and restricted cash - beginning of year	212,925,000	392,197,000	392,197,000
Plus: cash classified within current assets held for sale - beginning of year			0	$ 10,011,000
Cash, cash equivalents, and restricted cash - end of period	129,017,000	252,172,000	212,925,000
Reconciliation of cash, cash equivalents, and restricted cash to condensed consolidated balance sheets
Cash and cash equivalents	127,057,000	239,975,000	210,782,000
Restricted cash	1,960,000	12,197,000	2,143,000
Total cash, cash equivalents, and restricted cash	129,017,000	252,172,000	$ 212,925,000	$ 392,197,000
Supplemental disclosure of other cash flow information:
Cash paid for income taxes, net	451,000	187,000
Cash paid for interest	292,000	888,000
Supplemental disclosure of non-cash investing and financing activities:
Purchase of property and equipment and intangible assets recorded in accounts payable	$ 50,000	$ 790,000

Description of Business and Basis of Presentation

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business and Basis of Presentation

Basis of Presentation

Principles of Consolidation

Use of Estimates

Items subject to such estimates and assumptions include, but are not limited to:

•stock-based compensation expense;

•allowance for credit losses;

•the period of benefit for deferred contract acquisition costs;

•valuation of goodwill;

•valuation and useful lives of other long-lived assets;

•fair value of assets acquired and liabilities assumed in business combinations;

•income taxes; and

•recognition, measurement, and disclosure of contingent liabilities.

Significant Accounting Policies

Prepaid expenses and other current assets

The following table presents the detail of prepaid expenses and other current assets as of the dates presented:


	March 31, 2024		December 31, 2023

	(In thousands)
Prepaid software maintenance	$	6,065	$	8,592
VAT receivable	4,168		4,399
Prepaid server maintenance	2,824		2,634
Prepaid - other	2,743		2,599
Other assets	5,154		8,757
Total prepaid expenses and other current assets	$	20,954	$	26,981

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Revenue Recognition

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Revenue Recognition

The following table presents the Company’s revenues disaggregated by revenue source:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Revenue:
Hosted services (1)	$	71,495	$	87,338
Professional services	13,654		20,323
Total revenue	$	85,149	$	107,661

Remaining Performance Obligation

Revenue by Geographic Location


	Three Months Ended March 31,
	2024		2023

	(In thousands)
United States	$	60,507	$	68,509
Other Americas (1)	1,518		3,805
Total Americas	62,025		72,314
EMEA (2) (3)	14,221		16,182
APAC (4)	8,903		19,165
Total revenue	$	85,149	$	107,661

——————————————

(1)Canada, Latin America and South America

(2)Europe, the Middle East and Africa (“EMEA”)

(3)Includes revenue from the United Kingdom of $10.7 million and $15.3 million for the three months ended March 31, 2024 and 2023, respectively.

(4)Asia-Pacific (“APAC”)

Information about Contract Balances

The deferred revenue balance consists of services, which have been invoiced upfront, and are recognized as revenue only when the revenue recognition criteria are met.


	Accounts Receivable		Unbilled Receivable		Contract Acquisition Costs, Net (Non-current)		Deferred Revenue (Current)		Deferred Revenue (Non-current)

	(In thousands)
Balance as of December 31, 2022	$	53,468	$	33,069	$	43,804	$	84,494	$	174
Increase (decrease), net	6,914		(11,649)		(6,450)		(2,636)		9
Balance as of December 31, 2023	$	60,382	$	21,420	$	37,354	$	81,858	$	183
Increase (decrease), net	(6,177)		(4,260)		1,972		10,556		(60)
Balance as of March 31, 2024	$	54,205	$	17,160	$	39,326	$	92,414	$	123

Amortization expense in connection with contract acquisition cost was approximately $4.9 million and $8.3 million for the three months ended March 31, 2024 and 2023, respectively.

Accounts Receivable, Net


	March 31, 2024		December 31, 2023

	(In thousands)
Balance, beginning of year	$	9,290	9,239
Additions charged to costs and expenses	4,722		3,319
Deductions/write-offs	(4,777)		(3,268)
Balance, end of period	$	9,235	$	9,290

Net Loss Per Share

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Net Loss Per Share

The following table presents shares used in calculating basic and diluted EPS for the three months ended March 31, 2024 and 2023, as follows:


	Three Months Ended March 31,
	2024		2023

	(In thousands, except per share amounts)
Net loss	$	(35,631)	$	(17,420)
Weighted average number of shares outstanding, basic and diluted	88,081,654		75,774,812
Net loss per share, basic and diluted	$	(0.40)	$	(0.23)

Further, the following securities were excluded from the computation of diluted EPS, as their effect would have been anti-dilutive:


	As of March 31,
	2024	2023
Shares subject to outstanding common stock options and employee stock purchase plan	3,251,520	4,078,938
Restricted stock units	8,052,908	4,331,255
Earn-outs	—	23,818,594
Conversion option of the 2024 Notes	—	1,878,862
Conversion option of the 2026 Notes	6,879,283	6,879,283
Total	18,183,711	40,986,932

Segment Information

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Segment Information

Geographic Information


	March 31,		December 31,
	2024		2023

	(In thousands)
United States	$	430,731	$	438,420
Germany	41,778		45,424
Australia	11,865		11,660
Netherlands	5,843		5,863
Other (1)	13,135		12,438
Total long-lived assets	$	503,352	$	513,805

——————————————

(1)United Kingdom, Japan, France, Italy, Spain, Canada, and Singapore

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill and Intangible Assets, Net

Goodwill

The changes in the carrying amount of goodwill as of March 31, 2024 and December 31, 2023 are as follows:


	Consolidated

	(In thousands)
Balance as of December 31, 2022	$	296,214
Adjustments to goodwill:
Goodwill impairment (1)	(11,895)
Foreign exchange adjustment	1,312
Balance as of December 31, 2023	$	285,631
Adjustments to goodwill:

Goodwill impairment (1)	(3,627)
Foreign exchange adjustment	(1,048)
Balance as of March 31, 2024	$	280,956

(1) These amounts represent the entire accumulated goodwill impairment balance as of March 31, 2024.

Intangible Assets, Net

Intangible assets are summarized as follows:


	March 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Amortization Period

	(In thousands)						(In years)
Amortizing intangible assets:
Technology	$	94,562	$	(65,107)	$	29,455	5.0
Customer relationships	32,060		(20,057)		12,003		10.0
Patents	15,895		(2,066)		13,829		12.9
Trademarks	1,404		(761)		643		5.0
Trade names	1,044		(1,044)		—		2.8
Other	914		(835)		79		4.1
Total	$	145,879	$	(89,870)	$	56,009


	December 31, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Amortization Period

	(In thousands)						(In years)
Amortizing intangible assets:
Technology	$	94,549	$	(60,465)	$	34,084	5.0
Customer relationships	32,025		(19,542)		12,483		10.0
Patents	15,350		(1,916)		13,434		12.9
Trademarks	1,400		(707)		693		5.0
Trade names	1,044		(672)		372		2.8
Other	914		(355)		559		4.1
Total	$	145,282	$	(83,657)	$	61,625

As of March 31, 2024, estimated annual amortization expense for the next five years and thereafter is as follows:


	Estimated Amortization Expense
	(In thousands)
Remainder of 2024	$	11,567
2025	14,996
2026	12,160
2027	1,004
2028	821
Thereafter	15,461
Total	$	56,009

Property and Equipment

3 Months Ended

Mar. 31, 2024

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and Equipment, Net


	March 31, 2024		December 31, 2023		Useful life

	(In thousands)				(In years)
Internal-use software development costs	$	186,746	$	181,079	5
Computer equipment and software	126,728		123,580		3 to 5
Furniture, equipment and building improvements	329		327		The lesser of 5 or estimated useful life
Finance lease right-of-use assets	128		3,060		2
Property and equipment, at cost	313,931		308,046
Less: accumulated depreciation	(196,038)		(188,721)
Property and equipment, net	$	117,893	$	119,325

Depreciation and amortization expense of property and equipment was $8.2 million and $7.4 million during the three months ended March 31, 2024 and 2023, respectively.

Expenditures for routine maintenance and repairs are charged to operating expense as incurred. Major renewals and improvements are capitalized and depreciated over their estimated useful lives.

There were no impairments of property and equipment during the three months ended March 31, 2024 and 2023.

Total depreciation included in our condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 is as follows:


	March 31, 2024		March 31, 2023

	(In thousands)
Cost of revenue	$	1,682	$	2,247
Sales and marketing	900		726
General and administrative	158		161
Product development	5,485		4,228
Total	$	8,225	$	7,362

Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2024

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

The following table presents the detail of accrued expenses and other current liabilities for the periods presented:


	March 31, 2024		December 31, 2023

	(In thousands)
Professional services and consulting and other vendor fees	$	56,593	$	67,585
Payroll and other employee-related costs	13,214		20,767
Finance lease liability	104		3,037
Restructuring	1,808		2,076
Sales commissions	1,645		734
Non-income tax	556		556

Other	1,586		2,269
Total	$	75,506	$	97,024

Convertible Senior Notes and Capped Call Transactions

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Convertible Senior Notes and Capped Call Transactions

Convertible Senior Notes, Net of Current Portion and Capped Call Transactions

Convertible Senior Notes due 2024 and Capped Calls

As of March 31, 2024, there was no outstanding principal amount of the 2024 Notes.

Convertible Senior Notes due 2026 and Capped Calls

During the three months ended March 31, 2024, the conditions allowing holders of the 2026 Notes to convert were not met.

The 2026 Notes are senior unsecured obligations of the Company.


	March 31, 2024		December 31, 2023

	(In thousands)
Principal	$	517,500	$	589,992
Unamortized issuance costs	(5,424)		(6,034)
Total net carrying value	$	512,076	$	583,958
Less: short-term debt, net	—		72,393
Long-term debt, net	$	512,076	$	511,565

The following table sets forth the interest expense recognized related to the Notes:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Contractual interest expense	$	91	$	441
Amortization of debt issuance costs	610		920
Total interest expense	$	701	$	1,361

Leases

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

Leases

Supplemental cash flow information related to leases for the periods ended March 31, 2024 and 2023 is as follows:


	Three Months Ended
	March 31,
	2024		2023

	(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	842	$	974
Operating cash flows for finance leases	18		24
Financing cash flows for finance leases	327		958

The components of lease costs for the periods ended March 31, 2024 and 2023 are as follows:


	Three Months Ended
	March 31,
	2024		2023

	(In thousands)
Finance lease cost
Amortization of right of use assets	$	334	$	911
Interest	18		24
Operating lease cost	2,902		2,740
Total lease cost	$	3,254	$	3,675


	March 31, 2024		March 31, 2023
Weighted Average Remaining Lease Term:
Operating leases	2.0 years		1.7 years
Finance leases	1.6 years		1.0 year

Weighted Average Discount Rate:
Operating leases	7	%	7	%
Finance leases	7	%	4	%

Supplemental balance sheet information related to leases is as follows:


	Financial Statement Classification	March 31, 2024		December 31, 2023

		(In thousands)
Assets
Operating right-of-use assets	Operating lease right-of-use assets	$	3,431	$	4,135
Finance right-of-use assets	Property and equipment, net	128		3,060

Liabilities
Current liabilities:
Operating lease liabilities	Operating lease liabilities	$	2,632	$	2,719
Finance lease liabilities	Accrued expenses and other current liabilities	104		3,037
Non-current liabilities:
Operating lease liabilities	Operating lease liabilities, net of current portion	1,466		2,173
Finance lease liabilities	Other liabilities	55		85

Future minimum lease payments under non-cancellable operating and finance leases (with an initial or remaining lease term in excess of one year) are as follows:


	March 31, 2024
	Operating Leases		Finance Leases

	(In thousands)
2024 (remaining nine months for March 31, 2024)	$	2,186	$	83
2025	1,689		83
2026	316		—
2027	172		—
2028	86		—
Thereafter	—		—
Total minimum lease payments	4,449		166
Less: present value adjustment	(351)		(7)
Present value of lease liabilities	$	4,098	$	159

Fair Value Measurements

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value Measurements

•Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Financial Assets and Liabilities


	March 31, 2024
	Level 1		Level 2		Level 3		Total

	(In thousands)
Assets
Cash equivalents:
Money market funds	$	84,990	$	—	$	—	$	84,990
Total assets	$	84,990	$	—	$	—	$	84,990


	December 31, 2023
	Level 1		Level 2		Level 3		Total

	(In thousands)
Assets
Cash equivalents:
Money market funds	$	174,701	$	—	$	—	$	174,701
Total assets	$	174,701	$	—	$	—	$	174,701

The estimated fair value of outstanding balances of our 2024 Notes and 2026 Notes are as follows:


	Level of Hierarchy	Fair Value		Principal Balance		Unamortized Issuance Costs		Net Carrying Value

		(In thousands)
March 31, 2024
2026 Notes	2	$	367,497	$	517,500	$	(5,424)	$	512,076
December 31, 2023
2024 and 2026 Notes	2	$	435,883	$	589,992	$	(6,034)	$	583,958


	December 31, 2023


Balance, beginning of year	$	72,221
Additions in the period	—
Change in fair value of contingent consideration	4,629
Change in fair value of liability awards	(27,857)
Payments	(48,993)
Balance, end of year	$	—

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Employee Benefit Plans The Company has a 401(k) defined contribution plan covering all eligible employees. The Company’s 401(k) policy is a Safe Harbor Plan, whereby the Company matches 100% of the first 3% of eligible compensation and 50% of the next 2% of eligible compensation. Furthermore, the match is immediately vested. Salaries and related expenses include $1.1 million and $1.4 million of employer matching contributions for the three months ended March 31, 2024 and 2023, respectively. Letters of Credit As of March 31, 2024, the Company had letters of credit totaling $0.5 million outstanding as a security deposit for the due performance by the Company of the terms and conditions of a supply contract. Contractual obligations The Company’s purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. These purchase obligation agreements are primarily related to contracts with vendors in connection with Information Technology (“IT”) infrastructure and cloud computing-related services with remaining terms of two years or less. Our contractual obligations as of March 31, 2024, did not materially change from the amounts disclosed in our 2023 Annual Report on Form 10-K. Indemnifications The Company enters into service and license agreements in its ordinary course of business. Pursuant to some of these agreements, the Company agrees to indemnify certain customers from and against certain types of claims and losses suffered or incurred by them as a result of using the Company’s products. The Company also has agreements whereby its executive officers and directors are indemnified for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a directors and officers insurance policy that reduces its exposure and enables the Company to recover a portion of any future amounts paid subject to customary deductibles. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. The Company has no liabilities recorded for these agreements as of March 31, 2024 and December 31, 2023. Non-Income Related Taxes The Company is subject to sales tax liabilities, plus applicable interest, for states in which it has an economic nexus. The accrual balance for sales tax liabilities included within the condensed consolidated balance sheets was $0.6 million as of March 31, 2024 and December 31, 2023.

Stockholders' Equity

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Stockholders' Equity

Stockholders’ Equity

Stock-Based Compensation

Stock Option Plans

Employee Stock Purchase Plan

Inducement Plan

Stock Option Activity

The following table is a summary of the Company’s stock option activity for the three months ended March 31, 2024:


	Stock Option Activity				Weighted Average Remaining Contractual Term (In years)	Aggregate Intrinsic Value (In thousands)
	Options (In thousands)		Weighted Average Exercise Price
Balance outstanding at December 31, 2023	3,137		$	22.68	4.84	$	40
Granted	1,000	(1)	1.02
Exercised	—		—
Cancelled or expired	(885)		23.65
Balance outstanding at March 31, 2024	3,252		15.75		5.99	3
Options vested and expected to vest	647		9.30		3.71	—
Options exercisable at March 31, 2024	1,977		$	21.56	9.35	$	3

Restricted Stock Unit and Performance-Vesting Restricted Stock Unit Activity

The following table is a summary of the Company’s RSUs and PRSUs activity for the three months ended March 31, 2024:


	Number of Shares	Weighted Average Grant Date Fair Value		Aggregate Fair Value

	(In thousands)	(Per share)		(In thousands)
Balance outstanding at December 31, 2023	5,064	$	12.53	$	19,193
Awarded	3,893	1.17
Vested	(433)	16.94
Forfeited	(471)	16.61
Non-vested and outstanding at March 31, 2024	8,053	6.56		7,879
Expected to vest	5,285	$	7.02	$	5,153

Total stock-based compensation costs included in our condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 are as follows:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Cost of revenue	$	343	$	2,035
Sales and marketing	2,455		2,404
General and administrative	1,798		2,632
Product development	2,962		4,261
Total	$	7,558	$	11,332

Restructuring

3 Months Ended

Mar. 31, 2024

Restructuring and Related Activities [Abstract]

Restructuring


	March 31, 2024		December 31, 2023
	(In thousands)
Balance, beginning of the year	$	2,076	$	803

IT contract termination costs	715		5,744
Severance and other compensation associated costs	2,594		16,920
Cash payments	(3,577)		(21,391)
Balance, end of period	$	1,808	$	2,076

The Company anticipates that payments associated with the employee severance and other compensation associated costs reflected in the table above will be substantially completed by December 31, 2024.

The following table presents the detail of expenses for the Company’s restructuring charges for the three months ended March 31, 2024 and 2023:


	Three Months Ended
	March 31,
	2024		2023
	(In thousands)
Lease restructuring costs	$	—	$	1
IT contract termination costs	715		—
Severance and other associated costs	2,594		11,514
Total restructuring costs	$	3,309	$	11,515

Legal Matters	3 Months Ended
Legal Matters	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Legal Matters	Legal Matters Stockholder Litigation In December 2023, a putative stockholder class action entitled Damri v. LivePerson, Inc., No. 1:23-cv-10517, was filed under the federal securities laws against the Company, its former Chief Executive Officer, and its Chief Financial Officer in the United States District Court for the Southern District of New York. The complaint alleges that the Company’s Form 10-Q filings and forecasts for the first, second, and third quarters of fiscal year 2022 were false and misleading in violation of Section 10(b) of the Securities Exchange Act of 1934, based on the Company’s later disclosures and report on Form 10-K on March 16, 2023. A parallel litigation on behalf of stockholders who purchased their shares on the Tel Aviv Stock Exchange, entitled Weissbrod v. LivePerson, Inc., is pending in the Tel Aviv District Court in Israel, but has been stayed pending further developments in the Damri case. In January 2024, a purported derivative action entitled Marti v. LoCascio, No. 1:24-cv-00598, was filed in the United States District Court for the Southern District of New York by a purported stockholder of the Company against the Company’s former Chief Executive Officer, its Chief Financial Officer, most of the members of the current board of directors and several former directors. The derivative litigation claims that the Company itself was harmed by the same acts and omissions underlying the Damri federal securities lawsuit, and seeks to recover unspecified losses on behalf of the Company. The Marti case is stayed pending further developments in the Damri case. In January 2024, a purported stockholder of the Company filed a lawsuit against the Company and its Board of Directors entitled Browne v. Layfield, No. 2024-0079, in the Court of Chancery of the State of Delaware. The complaint asserted a claim for breach of fiduciary duty based upon a Tax Benefits Preservation Plan. In February 2024, the Board approved technical amendments to the Tax Benefits Preservation Plan which were filed by the Company on Form 8-K, and the case was dismissed as moot, subject to attorneys’ fees on behalf of the plaintiff. In February 2024, Starboard Value LP and several of its related entities and investment funds filed a lawsuit against the Company, its former Chief Executive Officer and its Chief Financial Officer entitled Starboard Value LP v. LivePerson, Inc., No. 2024-0103, in the Court of Chancery of the State of Delaware. The complaint alleges common law fraud, fraudulent inducement and negligent misrepresentation in connection with an alleged scheme to induce Starboard to settle its 2022 proxy contest against the Company and, as stated in the complaint, involves previous Starboard allegations of misrepresentations in the Company's public disclosures that the Company previously informed Starboard were found to be unsubstantiated following an independent investigation. The complaint seeks unspecified damages. The defendants have filed an answer denying the substantive allegations of the compliant. COVID-Related Matters As has been widely reported, there is heightened scrutiny by the federal government across many programs related to global novel coronavirus disease (“COVID-19”) that were introduced during the COVID-19 pandemic. The Company previously provided products and services related to COVID-19 testing and accompanying software. Those products and services have been the subject of inquiry and review by Medicare, the Department of Justice and the U.S. Food and Drug Administration. The Company has discontinued all products and services related to COVID-19, and has responded to and intends to continue to cooperate with governmental inquiries related to its previous engagement in COVID-19 related product and service offerings. Other Legal, Administrative, Governmental and Regulatory Matters From time to time, the Company is or may be subject to or involved in legal, administrative, governmental and/or regulatory proceedings, inquiries and investigations as well as actual or threatened litigation, claims and/or demands (each an “Action” and collectively “Actions”). These have included and may include (without limitation) Actions brought by or against the Company, its affiliates, subsidiaries, directors and/or officers with respect to intellectual property, contracts, financial, commercial, employment, legal, compliance, privacy, data security, regulatory and/or other matters related to our business, as well as Actions brought against the Company’s customers for which the Company has a contractual indemnification obligation. Regardless of the outcome, Actions can have an adverse impact on the Company because of defense and/or settlement costs, diversion of management resources, reputational risks and other factors. Accruals The Company accrues for certain contingencies when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated and discloses certain contingencies for which no accrual has been made as appropriate and in compliance with ASC 450, “Contingencies”. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. The accruals or estimates, if any, resulting from the foregoing analysis, are reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular matter.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are expected to become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company includes interest accrued on the underpayment of income taxes and certain interest expense and penalties, if any, related to unrecognized tax benefits as a component of the income tax provision. The Company maintains a valuation allowance against its U.S., e-bot7 Germany and Bulgaria deferred tax assets as it considered its cumulative losses in recent years as a significant piece of negative evidence. Since valuation allowances are evaluated by jurisdiction, the Company believes that the deferred tax assets related to LivePerson Australia Pty. Ltd., Engage Pty. Ltd., LivePerson (UK) Ltd., LivePerson Japan, and LivePerson Ltd. (Israel) are more likely than not to be realized as these jurisdictions have positive cumulative pre-tax book income after adjusting for permanent and one-time items. During the year ended December 31, 2023, there was an increase in the valuation allowance recorded of $23.7 million. For the three months ended March 31, 2024, the Company recorded a tax provision of $0.4 million. This entire amount consists of a tax provision on operating earnings of non-US subsidiaries and interest accrual on unrecognized tax benefits in Israel. The Company had a valuation allowance on certain deferred tax assets for the year ended December 31, 2023 of $211.2 million. Inherent in the Company’s 2024 annual effective tax rate is an estimated increase in the valuation allowance of $24.9 million, all of which would be recorded as an expense. During 2023, an increase in the valuation allowance in the amount of $23.7 million was recorded as an expense.

Equity Method Investments	3 Months Ended
Equity Method Investments	Mar. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	Equity Method Investment On February 13, 2022, the Company and Pasaca Capital Inc. (“Pasaca”) entered into a joint venture agreement (the “JV Agreement”) to form Claire Holdings, Inc. (“Claire”), a joint venture to build, create, and administer a marketplace for health and well-being diagnostic testing. Pursuant to the terms of the JV Agreement, the Company agreed to contribute a total of $19.0 million over a five-year period in exchange for a 19.2% ownership interest in Claire. Pasaca agreed to contribute $80.0 million to Claire over a five-year period in exchange for an 80.8% ownership interest in Claire. The Company accounts for its 19.2% interest in Claire using the equity method of accounting. The Company recorded its ownership percentage of losses of Claire in Other income (expense), net in the amount of $0.6 million for the three months ended March 31, 2023. The Company’s equity method investment in joint venture was reduced to zero during the prior year, based on the prior year losses, and remained at zero on the condensed consolidated balance sheet as of March 31, 2024. Refer to Note 18 – Related Parties for additional information.

Variable Interest Entity	3 Months Ended
Variable Interest Entity	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities The Company prepares its condensed consolidated financial statements in accordance with ASC 810, “Consolidation”, which provides for the consolidation of variable interest entities (“VIEs”) of which the Company is the primary beneficiary. In February 2022, the Company acquired WildHealth as well as certain variable interests that WildHealth has in four Professional Corporations (“PCs”). The PCs are owned by a medical practitioner in accordance with certain state laws which restrict the corporate practice of medicine and require medical practitioners to own such entities. WildHealth provides management and other services to the PCs in exchange for a management fee and provides financial support to the PCs through a revolving credit arrangement. WildHealth also has separate agreements with the equity holder of the PCs where it may acquire and assign such equity interests for certain PCs. The agreement entitles WildHealth to control rights sufficient to require the Company to consolidate the balance sheet and results of operations of the PCs as VIEs. The Company determined that the PCs are VIEs as WildHealth is the primary beneficiary of the PCs. The assets, liabilities, revenues, and operating results of the VIEs after elimination of intercompany transactions were not material as of and for the three months ended March 31, 2024.

Related Parties	3 Months Ended
Related Parties	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Parties	Related Parties Related parties are defined as entities related to the Company’s directors or main shareholders as well as equity method affiliates. During the year ended December 31, 2023, the Company provided services to Claire, an equity method affiliate (refer to Note 16 – Equity Method Investment for additional information on the equity method affiliate) in exchange for fees through certain commercial arrangements. These arrangements facilitated Claire’s build out and operations. In connection with the JV Agreement, the Company entered into commercial agreements with Claire, under which the Company agreed to provide custom software development and managed services in exchange for fees governed by the terms and conditions set forth therein. In accordance with guidance under ASC 606, Claire is considered a customer of the Company. No revenues were recognized for the services provided to Claire included in the Company’s condensed consolidated statements of operations for the three months ended March 31, 2024, compared to revenues of $3.8 million for the three months ended March 31, 2023. As of March 31, 2024, the Company has accounts receivable of $2.1 million included in the Company’s condensed consolidated balance sheet, which is fully recognized in its allowance for credit losses. Total accounts receivable of $2.1 million as of December 31, 2023 was included in the Company’s condensed consolidated balance sheet, for which the Company recognized $1.5 million in its allowance for credit losses.

Divestiture	3 Months Ended
Divestiture	Mar. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Divestiture	Divestiture Fiscal 2023 Divestitures In the fourth quarter of 2022, the Company entered into a non-binding Letter of Intent to divest Kasamba, Inc. and Kasamba LTD (together “Kasamba”), which represented the Company’s Consumer segment. Pursuant to ASC Subtopic 360-10, “Impairment or Disposal of Long-Lived Assets”, the Company applied held for sale accounting treatment to the assets and liabilities of Kasamba. Accordingly, the related net assets were separately presented in current assets and current liabilities as held for sale on the consolidated balance sheets as of December 31, 2022, up until the close of the transaction. The held for sale classification also resulted in ceasing depreciation and amortization on the designated assets. The Share Purchase Agreement between Ingenio, LLC (“Ingenio”) and the Company closed on March 20, 2023. In accordance with the Share Purchase Agreement, the Company sold all of the issued and outstanding shares of Kasamba for $16.9 million which was received in cash upon closing; and $2.6 million deferred payment to be received within a year of the close transaction date, which was included in prepaid expenses and other current assets on the Company’s condensed consolidated balance sheets as of March 31, 2023. $11.8 million was required to be held in various escrow accounts for up to 15 months, and was included in restricted cash on the Company’s consolidated balance sheets; however, $9.8 million of this escrow amount was released as of December 31, 2023. The transaction resulted in a gain of $17.6 million, which was recognized and presented separately as a gain on divestiture on the Company’s consolidated statements of operations during the year ended December 31, 2023. During the three months ended March 31, 2024, the Company recognized a post-closing adjustment pertaining to the final agreement in the amount of $1.8 million, which is recorded in General and administrative expenses in the condensed consolidated statement of operations.

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net loss (in thousands)	$ (35,631)	$ (17,420)

Insider Trading Arrangements

3 Months Ended

Mar. 31, 2024

Trading Arrangements, by Individual

Material Terms of Trading Arrangement

Trading Arrangement

Director/
Officer Name

Title

Date of Adoption/Termination

Rule 10b5-1

Trading Arrangement End Date

Aggregate Number of Securities to be Purchased or Sold

Bruce Hansen

Director

3/12/2024

Yes

3/06/2025

34,045

upon vesting of RSUs.

Alex Kroman

Chief Product & Technology Officer

3/12/2024

Yes

3/07/2025

185,875

upon vesting of RSUs and performance share awards.

Non-Rule 10b5-1 Arrangement Adopted

false

Rule 10b5-1 Arrangement Terminated

false

Non-Rule 10b5-1 Arrangement Terminated

false

Bruce Hansen [Member]

Trading Arrangements, by Individual

Name

Bruce Hansen

Title

Director

Rule 10b5-1 Arrangement Adopted

true

3/12/2024

359 days

34,045

Trading Arrangements, by Individual

Name

Alex Kroman

Title

Chief Product & Technology Officer

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

3/12/2024

Arrangement Duration

360 days

Aggregate Available

185,875

Description of Business and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements, and the financial data and other information disclosed in the notes to the condensed consolidated financial statements as of March 31, 2024 and for the three months ended March 31, 2024 are unaudited. In the opinion of management, the unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position, results of operations, comprehensive loss, and cash flows for the interim periods presented. The results of operations for any interim period are not necessarily indicative of the results of operations for any other future interim period or for a full fiscal year. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at that date. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 4, 2024.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements reflect the operations of LivePerson and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. These estimates are based on information available as of the date of the condensed consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to: •stock-based compensation expense; •allowance for credit losses; •the period of benefit for deferred contract acquisition costs; •valuation of goodwill; •valuation and useful lives of other long-lived assets; •fair value of assets acquired and liabilities assumed in business combinations; •income taxes; and •recognition, measurement, and disclosure of contingent liabilities. As of the date of issuance of the financial statements, the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions to clarify that a contractual restriction on the sale of an equity security is not considered part of a unit of account of the equity security, and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments also require the following disclosures for equity securities subject to the contractual sale restrictions: 1.) The fair value of equity securities subject to the contractual sale restrictions reflected on the balance sheet. 2.) The nature and remaining duration of the restriction(s). 3.) The circumstances that could cause a lapse in the restriction(s). This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within those financial years. The Company adopted this guidance on January 1, 2024, which did not have a material effect on the Company’s condensed consolidated financial statements. Recently Issued Accounting Pronouncements On March 21, 2024, the FASB issued ASU 2024-01, Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, which provides illustrative guidance to help entities determine whether profits interest and similar awards should be accounted for as share-based payment arrangements within the scope of FASB Accounting Standards Codification (“ASC”) 718, “Compensation—Stock Compensation.” Specifically, the amendments in ASU 2024-01 add an illustrative example that includes four fact patterns to demonstrate how an entity should apply the scope guidance in paragraph 718-10-15-3 to determine whether a profits interest award should be accounted for in accordance with Topic 718. The guidance in ASU 2024-01 applies to all entities that issue profits interest awards as compensation to employees or non-employees in exchange for goods or services. The amendments in this update are effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. ASU 2024-01 should be applied either retrospectively or prospectively. The Company does not expect this this standard to have a material impact on its condensed consolidated financial statements and related disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The updated standard is effective for annual periods beginning after December 15, 2023. The Company is currently evaluating the potential impact of adopting this new guidance on its condensed consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. The Company does not expect this standard to have a material impact on its condensed consolidated financial statements and related disclosures. In August 2023, the FASB issued ASU 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement, which addresses the accounting for contributions made to a joint venture, upon formation, in a joint venture’s separate financial statements. The amendments require certain joint ventures to apply a new basis of accounting upon formation by recognizing and initially measuring most of their assets and liabilities at fair value. The objectives of the amendments are to provide decision-useful information to investors and other allocators of capital in a joint venture’s financial statements and also to reduce diversity in practice. ASU 2023-05 is effective for both public and private joint venture entities with a formation date on or after January 1, 2025. Early adoption is permitted. Entities may elect to apply the guidance retrospectively to joint ventures with a formation date prior to January 1, 2025. The Company does not expect the adoption of this standard to have a material impact on its condensed consolidated financial statements and related disclosures.

Description of Business and Basis of Presentation (Tables)

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure

The following table presents the detail of prepaid expenses and other current assets as of the dates presented:


	March 31, 2024		December 31, 2023

	(In thousands)
Prepaid software maintenance	$	6,065	$	8,592
VAT receivable	4,168		4,399
Prepaid server maintenance	2,824		2,634
Prepaid - other	2,743		2,599
Other assets	5,154		8,757
Total prepaid expenses and other current assets	$	20,954	$	26,981

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table presents the Company’s revenues disaggregated by revenue source:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Revenue:
Hosted services (1)	$	71,495	$	87,338
Professional services	13,654		20,323
Total revenue	$	85,149	$	107,661

Schedule of Revenue by Geographic Region

The following table presents the Company’s revenues attributable to domestic and foreign operations for the periods presented:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
United States	$	60,507	$	68,509
Other Americas (1)	1,518		3,805
Total Americas	62,025		72,314
EMEA (2) (3)	14,221		16,182
APAC (4)	8,903		19,165
Total revenue	$	85,149	$	107,661

——————————————

(1)Canada, Latin America and South America

(2)Europe, the Middle East and Africa (“EMEA”)

(3)Includes revenue from the United Kingdom of $10.7 million and $15.3 million for the three months ended March 31, 2024 and 2023, respectively.

(4)Asia-Pacific (“APAC”)

Schedule Of Receivables, Contract Acquisition Costs, And Deferred Revenue

The opening and closing balances of the Company’s accounts receivable, unbilled receivables, and deferred revenues are as follows:


	Accounts Receivable		Unbilled Receivable		Contract Acquisition Costs, Net (Non-current)		Deferred Revenue (Current)		Deferred Revenue (Non-current)

	(In thousands)
Balance as of December 31, 2022	$	53,468	$	33,069	$	43,804	$	84,494	$	174
Increase (decrease), net	6,914		(11,649)		(6,450)		(2,636)		9
Balance as of December 31, 2023	$	60,382	$	21,420	$	37,354	$	81,858	$	183
Increase (decrease), net	(6,177)		(4,260)		1,972		10,556		(60)
Balance as of March 31, 2024	$	54,205	$	17,160	$	39,326	$	92,414	$	123

Amortization expense in connection with contract acquisition cost was approximately $4.9 million and $8.3 million for the three months ended March 31, 2024 and 2023, respectively.

Schedule of Allowance for Uncollectible Accounts

The activity in the allowance for credit losses is as follows:


	March 31, 2024		December 31, 2023

	(In thousands)
Balance, beginning of year	$	9,290	9,239
Additions charged to costs and expenses	4,722		3,319
Deductions/write-offs	(4,777)		(3,268)
Balance, end of period	$	9,235	$	9,290

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Reconciliation of Shares Used in Calculating Basic and Diluted Earnings Per Share

The following table presents shares used in calculating basic and diluted EPS for the three months ended March 31, 2024 and 2023, as follows:


	Three Months Ended March 31,
	2024		2023

	(In thousands, except per share amounts)
Net loss	$	(35,631)	$	(17,420)
Weighted average number of shares outstanding, basic and diluted	88,081,654		75,774,812
Net loss per share, basic and diluted	$	(0.40)	$	(0.23)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Further, the following securities were excluded from the computation of diluted EPS, as their effect would have been anti-dilutive:


	As of March 31,
	2024	2023
Shares subject to outstanding common stock options and employee stock purchase plan	3,251,520	4,078,938
Restricted stock units	8,052,908	4,331,255
Earn-outs	—	23,818,594
Conversion option of the 2024 Notes	—	1,878,862
Conversion option of the 2026 Notes	6,879,283	6,879,283
Total	18,183,711	40,986,932

Segment Information (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedule of Long-Lived Assets by Geographic Region


	March 31,		December 31,
	2024		2023

	(In thousands)
United States	$	430,731	$	438,420
Germany	41,778		45,424
Australia	11,865		11,660
Netherlands	5,843		5,863
Other (1)	13,135		12,438
Total long-lived assets	$	503,352	$	513,805

——————————————

(1)United Kingdom, Japan, France, Italy, Spain, Canada, and Singapore

Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill as of March 31, 2024 and December 31, 2023 are as follows:


	Consolidated

	(In thousands)
Balance as of December 31, 2022	$	296,214
Adjustments to goodwill:
Goodwill impairment (1)	(11,895)
Foreign exchange adjustment	1,312
Balance as of December 31, 2023	$	285,631
Adjustments to goodwill:

Goodwill impairment (1)	(3,627)
Foreign exchange adjustment	(1,048)
Balance as of March 31, 2024	$	280,956

Summary of Intangible Assets

Intangible assets are summarized as follows:


	March 31, 2024
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Amortization Period

	(In thousands)						(In years)
Amortizing intangible assets:
Technology	$	94,562	$	(65,107)	$	29,455	5.0
Customer relationships	32,060		(20,057)		12,003		10.0
Patents	15,895		(2,066)		13,829		12.9
Trademarks	1,404		(761)		643		5.0
Trade names	1,044		(1,044)		—		2.8
Other	914		(835)		79		4.1
Total	$	145,879	$	(89,870)	$	56,009


	December 31, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Amortization Period

	(In thousands)						(In years)
Amortizing intangible assets:
Technology	$	94,549	$	(60,465)	$	34,084	5.0
Customer relationships	32,025		(19,542)		12,483		10.0
Patents	15,350		(1,916)		13,434		12.9
Trademarks	1,400		(707)		693		5.0
Trade names	1,044		(672)		372		2.8
Other	914		(355)		559		4.1
Total	$	145,282	$	(83,657)	$	61,625

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

As of March 31, 2024, estimated annual amortization expense for the next five years and thereafter is as follows:


	Estimated Amortization Expense
	(In thousands)
Remainder of 2024	$	11,567
2025	14,996
2026	12,160
2027	1,004
2028	821
Thereafter	15,461
Total	$	56,009

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2024

Property, Plant and Equipment [Abstract]

Summary of Property and Equipment

The following table presents the detail of property and equipment, net for the periods presented:


	March 31, 2024		December 31, 2023		Useful life

	(In thousands)				(In years)
Internal-use software development costs	$	186,746	$	181,079	5
Computer equipment and software	126,728		123,580		3 to 5
Furniture, equipment and building improvements	329		327		The lesser of 5 or estimated useful life
Finance lease right-of-use assets	128		3,060		2
Property and equipment, at cost	313,931		308,046
Less: accumulated depreciation	(196,038)		(188,721)
Property and equipment, net	$	117,893	$	119,325

Total depreciation included in our condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 is as follows:


	March 31, 2024		March 31, 2023

	(In thousands)
Cost of revenue	$	1,682	$	2,247
Sales and marketing	900		726
General and administrative	158		161
Product development	5,485		4,228
Total	$	8,225	$	7,362

Accrued Expenses and Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2024

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

The following table presents the detail of accrued expenses and other current liabilities for the periods presented:


	March 31, 2024		December 31, 2023

	(In thousands)
Professional services and consulting and other vendor fees	$	56,593	$	67,585
Payroll and other employee-related costs	13,214		20,767
Finance lease liability	104		3,037
Restructuring	1,808		2,076
Sales commissions	1,645		734
Non-income tax	556		556

Other	1,586		2,269
Total	$	75,506	$	97,024

Convertible Senior Notes and Capped Call Transactions (Tables)

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Schedule of Carrying Amount of Liability Component of Convertible Debt

The net carrying amount of the liability component of the Notes as of March 31, 2024 and December 31, 2023 is as follows:


	March 31, 2024		December 31, 2023

	(In thousands)
Principal	$	517,500	$	589,992
Unamortized issuance costs	(5,424)		(6,034)
Total net carrying value	$	512,076	$	583,958
Less: short-term debt, net	—		72,393
Long-term debt, net	$	512,076	$	511,565

Schedule of Interest Expense Incurred

The following table sets forth the interest expense recognized related to the Notes:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Contractual interest expense	$	91	$	441
Amortization of debt issuance costs	610		920
Total interest expense	$	701	$	1,361

Leases (Tables)

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

Supplemental cash flow information related to leases

Supplemental cash flow information related to leases for the periods ended March 31, 2024 and 2023 is as follows:


	Three Months Ended
	March 31,
	2024		2023

	(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	842	$	974
Operating cash flows for finance leases	18		24
Financing cash flows for finance leases	327		958

Schedule of components of lease costs

The components of lease costs for the periods ended March 31, 2024 and 2023 are as follows:


	Three Months Ended
	March 31,
	2024		2023

	(In thousands)
Finance lease cost
Amortization of right of use assets	$	334	$	911
Interest	18		24
Operating lease cost	2,902		2,740
Total lease cost	$	3,254	$	3,675


	March 31, 2024		March 31, 2023
Weighted Average Remaining Lease Term:
Operating leases	2.0 years		1.7 years
Finance leases	1.6 years		1.0 year

Weighted Average Discount Rate:
Operating leases	7	%	7	%
Finance leases	7	%	4	%

Supplemental balance sheet information related to leases

Supplemental balance sheet information related to leases is as follows:


	Financial Statement Classification	March 31, 2024		December 31, 2023

		(In thousands)
Assets
Operating right-of-use assets	Operating lease right-of-use assets	$	3,431	$	4,135
Finance right-of-use assets	Property and equipment, net	128		3,060

Liabilities
Current liabilities:
Operating lease liabilities	Operating lease liabilities	$	2,632	$	2,719
Finance lease liabilities	Accrued expenses and other current liabilities	104		3,037
Non-current liabilities:
Operating lease liabilities	Operating lease liabilities, net of current portion	1,466		2,173
Finance lease liabilities	Other liabilities	55		85

Schedule of Future Minimum Lease Payments

Future minimum lease payments under non-cancellable operating and finance leases (with an initial or remaining lease term in excess of one year) are as follows:


	March 31, 2024
	Operating Leases		Finance Leases

	(In thousands)
2024 (remaining nine months for March 31, 2024)	$	2,186	$	83
2025	1,689		83
2026	316		—
2027	172		—
2028	86		—
Thereafter	—		—
Total minimum lease payments	4,449		166
Less: present value adjustment	(351)		(7)
Present value of lease liabilities	$	4,098	$	159

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value

The Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy as of March 31, 2024 and December 31, 2023, are summarized as follows:


	March 31, 2024
	Level 1		Level 2		Level 3		Total

	(In thousands)
Assets
Cash equivalents:
Money market funds	$	84,990	$	—	$	—	$	84,990
Total assets	$	84,990	$	—	$	—	$	84,990


	December 31, 2023
	Level 1		Level 2		Level 3		Total

	(In thousands)
Assets
Cash equivalents:
Money market funds	$	174,701	$	—	$	—	$	174,701
Total assets	$	174,701	$	—	$	—	$	174,701

Schedule of Carrying Values and Estimated Fair Values of Debt Instruments

The estimated fair value of outstanding balances of our 2024 Notes and 2026 Notes are as follows:


	Level of Hierarchy	Fair Value		Principal Balance		Unamortized Issuance Costs		Net Carrying Value

		(In thousands)
March 31, 2024
2026 Notes	2	$	367,497	$	517,500	$	(5,424)	$	512,076
December 31, 2023
2024 and 2026 Notes	2	$	435,883	$	589,992	$	(6,034)	$	583,958

Schedule of Changes in Fair Value of Level 3 Liabilities

The changes in fair value of the Level 3 liabilities during the annual period ended December 31, 2023 are as follows:


	December 31, 2023


Balance, beginning of year	$	72,221
Additions in the period	—
Change in fair value of contingent consideration	4,629
Change in fair value of liability awards	(27,857)
Payments	(48,993)
Balance, end of year	$	—

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Summary of Stock Option Activity and Weighted Average Exercise Prices

The following table is a summary of the Company’s stock option activity for the three months ended March 31, 2024:


	Stock Option Activity				Weighted Average Remaining Contractual Term (In years)	Aggregate Intrinsic Value (In thousands)
	Options (In thousands)		Weighted Average Exercise Price
Balance outstanding at December 31, 2023	3,137		$	22.68	4.84	$	40
Granted	1,000	(1)	1.02
Exercised	—		—
Cancelled or expired	(885)		23.65
Balance outstanding at March 31, 2024	3,252		15.75		5.99	3
Options vested and expected to vest	647		9.30		3.71	—
Options exercisable at March 31, 2024	1,977		$	21.56	9.35	$	3

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

The following table is a summary of the Company’s RSUs and PRSUs activity for the three months ended March 31, 2024:


	Number of Shares	Weighted Average Grant Date Fair Value		Aggregate Fair Value

	(In thousands)	(Per share)		(In thousands)
Balance outstanding at December 31, 2023	5,064	$	12.53	$	19,193
Awarded	3,893	1.17
Vested	(433)	16.94
Forfeited	(471)	16.61
Non-vested and outstanding at March 31, 2024	8,053	6.56		7,879
Expected to vest	5,285	$	7.02	$	5,153

Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award

Total stock-based compensation costs included in our condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 are as follows:


	Three Months Ended March 31,
	2024		2023

	(In thousands)
Cost of revenue	$	343	$	2,035
Sales and marketing	2,455		2,404
General and administrative	1,798		2,632
Product development	2,962		4,261
Total	$	7,558	$	11,332

Restructuring (Tables)

3 Months Ended

Mar. 31, 2024

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs


	March 31, 2024		December 31, 2023
	(In thousands)
Balance, beginning of the year	$	2,076	$	803

IT contract termination costs	715		5,744
Severance and other compensation associated costs	2,594		16,920
Cash payments	(3,577)		(21,391)
Balance, end of period	$	1,808	$	2,076

The Company anticipates that payments associated with the employee severance and other compensation associated costs reflected in the table above will be substantially completed by December 31, 2024.

Schedule of Restructuring Liability by Cost Type

The following table presents the detail of expenses for the Company’s restructuring charges for the three months ended March 31, 2024 and 2023:


	Three Months Ended
	March 31,
	2024		2023
	(In thousands)
Lease restructuring costs	$	—	$	1
IT contract termination costs	715		—
Severance and other associated costs	2,594		11,514
Total restructuring costs	$	3,309	$	11,515

Description of Business and Basis of Presentation (Details)	Mar. 31, 2024 connection
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number Of Connections And Conversations Powered Each Month	1,000,000,000

Description of Business and Basis of Presentation - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Prepaid software maintenance	$ 6,065	$ 8,592
VAT receivable	4,168	4,399
Prepaid server maintenance	2,824	2,634
Prepaid - other	2,743	2,599
Other assets	5,154	8,757
Prepaid expenses and other current assets (Note 1)	$ 20,954	$ 26,981

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Revenue from related parties	$ 85,149	$ 107,661
Hosted Services - Business
Disaggregation of Revenue [Line Items]
Revenue from related parties	71,495	87,338
Professional Services
Disaggregation of Revenue [Line Items]
Revenue from related parties	$ 13,654	20,323
Hosted Services - Consumer \| Kasamba, Inc.
Disaggregation of Revenue [Line Items]
Revenue from related parties		$ 7,200

Revenue Recognition - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Remaining performance obligation	$ 296,700
Percentage of remaining performance obligations to be recognized over next 24 months	91.00%
Recognition of deferred revenue	$ 42,500	$ 44,100

Revenue Recognition - Revenue by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Revenue from related parties	$ 85,149	$ 107,661
United States
Disaggregation of Revenue [Line Items]
Revenue from related parties	60,507	68,509
Other Americas
Disaggregation of Revenue [Line Items]
Revenue from related parties	1,518	3,805
Total Americas
Disaggregation of Revenue [Line Items]
Revenue from related parties	62,025	72,314
EMEA
Disaggregation of Revenue [Line Items]
Revenue from related parties	14,221	16,182
APAC
Disaggregation of Revenue [Line Items]
Revenue from related parties	8,903	19,165
United Kingdom
Disaggregation of Revenue [Line Items]
Revenue from related parties	$ 10,700	$ 15,300

Revenue Recognition - Receivables and Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Contract Balances [Roll Forward]
Accounts receivable, opening balance	$ 81,802
Accounts receivable, ending balance	71,365		$ 81,802
Contract acquisition costs noncurrent, opening balance	37,354	$ 43,804	43,804
Contract acquisition costs noncurrent, increase (decrease), net	1,972		(6,450)
Contract acquisition costs noncurrent, ending balance	39,326		37,354
Deferred revenue (current), opening balance	81,858	84,494	84,494
Deferred revenue (current), increase (decrease), net	10,556		(2,636)
Deferred revenue (current), ending balance	92,414		81,858
Deferred revenue (long-term), opening balance	183	174	174
Deferred revenue (long-term), increase (decrease), net	(60)		9
Deferred revenue (long-term), ending balance	123		183
Amortization of acquisition costs	4,900	8,300
Billed receivable
Contract Balances [Roll Forward]
Accounts receivable, opening balance	60,382	53,468	53,468
Accounts receivable, increase (decrease), net	(6,177)		6,914
Accounts receivable, ending balance	54,205		60,382
Unbilled receivable
Contract Balances [Roll Forward]
Accounts receivable, opening balance	21,420	$ 33,069	33,069
Accounts receivable, increase (decrease), net	(4,260)		(11,649)
Accounts receivable, ending balance	$ 17,160		$ 21,420

Revenue Recognition - Accounts Receivable (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Allowance for Doubtful Accounts
Beginning balance	$ 9,290	$ 9,239	$ 9,239
Additions charged to costs and expenses	4,722	$ 1,079	3,319
Deductions/write-offs	(4,777)		(3,268)
Ending balance	$ 9,235		$ 9,290

Net Loss Per Share - Narrative (Details) - Convertible Debt		1 Months Ended
	Dec. 31, 2020	Mar. 31, 2019	Dec. 31, 2022
2024 Notes
Debt Instrument [Line Items]
Debt instrument stated rate (percent)		0.75%
Debt Instrument, Convertible, Conversion Ratio		0.0259182
2026 Notes
Debt Instrument [Line Items]
Debt instrument stated rate (percent)			0.00%
Debt Instrument, Convertible, Conversion Ratio	0.0132933

Net Loss Per Share - Reconciliation of Shares Used in Calculating Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Net income (loss) available to common stockholders, basic	$ (35,631)	$ (17,420)
Weighted-average shares used to compute basic net income per share (in shares)	88,081,654	75,774,812
Diluted (in shares)	88,081,654	75,774,812
Basic (in dollars per share)	$ (0.40)	$ (0.23)
Diluted (in dollars per share)	$ (0.40)	$ (0.23)

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of EPS (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock awards not included in earnings per share calculation (in shares)	18,183,711	40,986,932
Shares subject to outstanding common stock options and employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock awards not included in earnings per share calculation (in shares)	3,251,520	4,078,938
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock awards not included in earnings per share calculation (in shares)	8,052,908	4,331,255
Fair Value Earnout
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock awards not included in earnings per share calculation (in shares)	0	23,818,594
Conversion option of the Notes \| 2024 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock awards not included in earnings per share calculation (in shares)	0	1,878,862
Conversion option of the Notes \| 2026 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock awards not included in earnings per share calculation (in shares)	6,879,283	6,879,283

Segment Information - Narrative (Details) - segment	3 Months Ended
Segment Information - Narrative (Details) - segment	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting [Abstract]
Number of operating segments	1	2
Number of reportable segments	1

Segment Information - Long-Lived Assets by Geographic Region (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Total long-lived assets	$ 503,352	$ 513,805
United States
Segment Reporting Information [Line Items]
Total long-lived assets	430,731	438,420
Germany
Segment Reporting Information [Line Items]
Total long-lived assets	41,778	45,424
Australia
Segment Reporting Information [Line Items]
Total long-lived assets	11,865	11,660
Netherlands
Segment Reporting Information [Line Items]
Total long-lived assets	5,843	5,863
Other
Segment Reporting Information [Line Items]
Total long-lived assets	$ 13,135	$ 12,438

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 285,631
Impairment of goodwill	(3,627)	$ 0	$ (11,895)
Goodwill, ending balance	280,956		285,631
Business
Goodwill [Roll Forward]
Goodwill, beginning balance	285,631	$ 296,214	296,214
Foreign exchange adjustment	(1,048)		1,312
Goodwill, ending balance	$ 280,956		$ 285,631

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 145,879	$ 145,282
Accumulated Amortization	(89,870)	(83,657)
Net Carrying Amount	56,009	61,625
Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	94,562	94,549
Accumulated Amortization	(65,107)	(60,465)
Net Carrying Amount	$ 29,455	$ 34,084
Weighted Average Useful Life	5 years	5 years
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 32,060	$ 32,025
Accumulated Amortization	(20,057)	(19,542)
Net Carrying Amount	$ 12,003	$ 12,483
Weighted Average Useful Life	10 years	10 years
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 15,895	$ 1,400
Accumulated Amortization	(2,066)	(707)
Net Carrying Amount	$ 13,829	$ 693
Weighted Average Useful Life	12 years 10 months 24 days	2 years 9 months 18 days
Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,404	$ 1,044
Accumulated Amortization	(761)	(672)
Net Carrying Amount	$ 643	$ 372
Weighted Average Useful Life	5 years	5 years
Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,044	$ 15,350
Accumulated Amortization	(1,044)	(1,916)
Net Carrying Amount	$ 0	$ 13,434
Weighted Average Useful Life	2 years 9 months 18 days	12 years 10 months 24 days
Other
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 914	$ 914
Accumulated Amortization	(835)	(355)
Net Carrying Amount	$ 79	$ 559
Weighted Average Useful Life	4 years 1 month 6 days	4 years 1 month 6 days

Goodwill and Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Goodwill [Line Items]
Impairment of goodwill	$ 3,627,000	$ 0	$ 11,895,000
Amortization of purchased intangible assets	891,000	874,000
Impairment of intangible assets	2,221,000	0
WildHealth
Goodwill [Line Items]
Impairment of goodwill	3,600,000
Other Asset Impairment Charges	2,200,000
Cost of revenue
Goodwill [Line Items]
Amortization of purchased intangible assets	4,200,000	5,400,000
Amortization of purchased intangibles	$ 3,300,000	$ 4,600,000

Goodwill and Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Estimated Amortization Expense
Remainder of 2024	$ 11,567
2025	14,996
2026	12,160
2027	1,004
2028	821
Thereafter	15,461
Total	$ 56,009	$ 61,625

Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Finance lease right-of-use assets	$ 128	$ 3,060
Property and equipment and finance lease, gross	313,931	308,046
Less: accumulated depreciation	(196,038)	(188,721)
Property and equipment, net	$ 117,893	119,325
Finance lease, term of contract	2 years
Internal-use software development costs
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 186,746	181,079
Useful life	5 years
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 126,728	123,580
Computer equipment and software \| Minimum
Property, Plant and Equipment [Line Items]
Useful life	3 years
Computer equipment and software \| Maximum
Property, Plant and Equipment [Line Items]
Useful life	5 years
Finance lease right-of-use assets
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 329	$ 327
Useful life	5 years

Property and Equipment - Narrative (Details) - USD ($)	3 Months Ended
Property and Equipment - Narrative (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 8,200,000	$ 7,400,000
Impairment, Long-Lived Asset, Held-for-Use	$ 0	$ 0

Property and Equipment - Schedule of Depreciation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 8,225	$ 7,362
Cost of revenue
Property, Plant and Equipment [Line Items]
Depreciation expense	1,682	2,247
Sales and marketing
Property, Plant and Equipment [Line Items]
Depreciation expense	900	726
General and administrative
Property, Plant and Equipment [Line Items]
Depreciation expense	158	161
Product development
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 5,485	$ 4,228

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Professional services and consulting and other vendor fees	$ 56,593	$ 67,585
Payroll and other employee-related costs	13,214	20,767
Finance lease liability	104	3,037
Restructuring	1,808	2,076	$ 803
Sales commissions	1,645	734
Non-income tax	556	556
Other	1,586	2,269
Total	$ 75,506	$ 97,024

Convertible Senior Notes and Capped Call Transactions - Narrative (Details) $ / shares in Units, shares in Thousands, $ in Thousands			1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 21, 2023 USD ($)	Dec. 31, 2020	Dec. 31, 2020 USD ($) day shares	Mar. 31, 2019 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2024 $ / shares	Dec. 31, 2023 $ / shares	Dec. 31, 2022 USD ($) $ / shares
Debt Instrument [Line Items]
Debt instrument, repurchase amount	$ 149,700
Debt instrument, increase (decrease), net	157,500
Convertible senior notes, net of current portion (Note 8)					$ 512,076		$ 511,565
Number of shares of common stock covered by called caps (shares) \| shares			6,880
Reduction to additional paid-in-capital related to called caps			$ 46,100
Interest expense					700	$ 1,400
Common stock, par value (in dollars per share) \| (per share)									$ 1.000	$ 1.000	$ 0.001
2024 Notes
Debt Instrument [Line Items]
Principal Balance					72,000
Debt instrument, increase (decrease), net	$ 228,300
Gain (loss) on extinguishment of debt							7,200
2024 Notes \| Previously Reported
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt						6,100
Payment for debt extinguishment or debt prepayment cost						$ 500
2024 Notes \| Revision of Prior Period, Adjustment
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt							$ 1,100
2024 Notes \| Convertible Debt
Debt Instrument [Line Items]
Principal Balance				$ 230,000	72,500
Debt instrument stated rate (percent)				0.75%
Debt Instrument, Convertible, Conversion Ratio				0.0259182
2026 Notes
Debt Instrument [Line Items]
Convertible senior notes, net of current portion (Note 8)					512,100
Unamortized issuance costs					$ 5,400
2026 Notes \| Convertible Debt
Debt Instrument [Line Items]
Principal Balance											$ 517,500
Debt instrument stated rate (percent)											0.00%
Proceeds from debt offering, net of debt issuance costs								$ 505,300
Debt Instrument, Convertible, Conversion Ratio		0.0132933
Percentage of principal amount paid if repurchase due to fundamental change (percent)			100.00%
Threshold trading days in consideration of note conversion \| day			20
Threshold consecutive trading days in analysis of conversion price \| day			30
Threshold percentage of stock price if converted			130.00%
Debt Instrument, Convertible Business Period		5 years
Debt Instrument, Convertible, Measurement Period		5 years
Threshold for five day period, product of sale price of common stock and conversion rate of notes			98.00%
Remaining amortization period for debt discount and debt issuance costs					2 years 8 months 12 days
Effective interest rate (percent)					0.40%
Convertible debt conversion price (in dollars per share) \| $ / shares											$ 75.23
Capped calls
Debt Instrument [Line Items]
Capped caps initial strike price (in dollars per share) \| $ / shares											75.23
Capped caps initial cap price (in dollars per share) \| $ / shares											$ 105.58

Convertible Senior Notes and Capped Call Transactions - Schedule of Carrying Amount of Liability Component of Convertible Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total net carrying value	$ 512,076	$ 583,958
Less: short-term debt, net	0	72,393
Long-term debt, net	512,076	511,565
Convertible Debt \| Convertible Senior Notes
Debt Instrument [Line Items]
Principal	517,500	589,992
Unamortized issuance costs	$ 5,424	$ 6,034

Convertible Senior Notes and Capped Call Transactions - Schedule of Interest Expense Incurred (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Debt Instrument [Line Items]
Amortization of debt issuance costs	$ 610	$ 920
Total interest expense	700	1,400
Convertible Senior Notes \| Convertible Debt
Debt Instrument [Line Items]
Contractual interest expense	91	441
Amortization of debt issuance costs	610	920
Total interest expense	$ 701	$ 1,361

Leases (Narrative) (Details)	Mar. 31, 2024
Minimum
Lessee, Lease, Description [Line Items]
Operating leases remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Operating leases remaining lease term	5 years

Leases (Supplemental cash flow information related to leases) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Operating cash flows for operating leases	$ 842	$ 974
Operating cash flows for finance leases	18	24
Financing cash flows for finance leases	$ 327	$ 958

Leases (Schedule of components of lease costs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Amortization of right of use assets	$ 334	$ 911
Interest	18	24
Operating lease cost	2,902	2,740
Total lease cost	$ 3,254	$ 3,675
Operating leases, weighted average remaining lease term (in years)	2 years	1 year 8 months 12 days
Finance leases, weighted average remaining lease term (in years)	1 year 7 months 6 days	1 year
Operating leases, weighted average discount rate (percent)	7.00%	7.00%
Finance leases, weighted average discount rate (percent)	7.00%	4.00%

Leases (Supplemental balance sheet information related to leases) (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
ASSETS
Operating right of use assets	$ 3,431	$ 4,135
Finance right of use assets	128	3,060
Current liabilities:
Operating Lease, Liability, Current	2,632	2,719
Finance lease liability	104	3,037
Non-current:
Operating Lease, Liability, Noncurrent	1,466	2,173
Finance lease liabilities	$ 55	$ 85

Leases (Schedule of Future Minimum Lease Payments) (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Operating Leases
2023 (remaining three months for March 31, 2024)	$ 2,186
2024	1,689
2025	316
2026	172
2027	86
Thereafter	0
Total minimum lease payments	4,449
Less: present value adjustment	(351)
Operating lease, liability	4,098
Finance Leases
2023 (remaining three months for March 31, 2024)	83
2024	83
2025	0
2026	0
2027	0
Finance Lease Liability Payment Due After Year Four	0
Total minimum lease payments	166
Less: present value adjustment	(7)
Present value of lease liabilities	$ 159

Fair Value Measurements - Financial Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Money market funds	$ 84,990	$ 174,701
Total assets	84,990	174,701
Recurring \| Level 1
Assets
Money market funds	84,990
Total assets	84,990	174,701
Recurring \| Level 2
Assets
Money market funds	0
Total assets	0	0
Recurring \| Level 3
Assets
Money market funds	0
Total assets	$ 0	$ 0

Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Change in Fair Value of Level 3 Liabilities
Beginning balance	$ 72,221
Additions in the period	0
Payments	(48,993)
Ending balance	0
Contingent Liability
Change in Fair Value of Level 3 Liabilities
Change in fair value of liability awards	4,629
Liability Awards
Change in Fair Value of Level 3 Liabilities
Change in fair value of liability awards	$ (27,857)

Fair Value Measurements - Narrative (Details) $ in Millions	3 Months Ended
Fair Value Measurements - Narrative (Details) $ in Millions	Mar. 31, 2024 USD ($)
WildHealth
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payments for previous acquisition	$ 12.0
VoiceBase, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payments for previous acquisition	19.9
Tenfold
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payments for previous acquisition	9.3
ebot-7
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payments for previous acquisition	$ 7.7

Fair Value Measurements - Schedule of Carrying Value and Fair Value of Debt Instruments (Details) - Level 2 - Convertible Senior Notes Due 2024 and 2026 - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 367,497	$ 435,883
Principal Balance	517,500	589,992
Unamortized Issuance Costs	(5,424)	(6,034)
Net Carrying Value	$ 512,076	$ 583,958

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Other Commitments [Line Items]
Employer matching contributions	$ 1.1	$ 1.4
Long-term purchase commitment, period	2 years
Accrued sales tax, including interest	$ 0.6		$ 0.6
Letter of Credit \| LOC for Security Deposit
Other Commitments [Line Items]
Letters of credit outstanding, amount	$ 0.5
Match Step One
Other Commitments [Line Items]
Employer matching contribution, percent of match	100.00%
Employer matching contribution percent of eligible compensation	3.00%
Match Step Two
Other Commitments [Line Items]
Employer matching contribution, percent of match	50.00%
Employer matching contribution percent of eligible compensation	2.00%

Stockholders' Equity - Summary of Stock Option Activity and Weighted Average Exercise Prices (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Options
Beginning balance (in shares)	3,137
Granted (in shares)	1,000
Exercised (in shares)	0
Cancelled or expired (in shares)	(885)
Ending balance (in shares)	3,252	3,137
Options vested and expected to vest (in shares)	647
Options exercisable at end of period (in shares)	1,977
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 22.68
Granted (in dollars per share)	1.02
Exercised (in dollars per share)	0
Cancelled or expired (in dollars per share)	23.65
Ending balance (in dollars per share)	15.75	$ 22.68
Options vested and expected to vest (in dollars per share)	9.30
Options exercisable at end of period (in dollars per share)	$ 21.56
Weighted Average Remaining Contractual Term
Weighted average remaining contract term, Options outstanding	5 years 11 months 26 days	4 years 10 months 2 days
Weighted average remaining contract term, Options vested and expected to vest	3 years 8 months 15 days
Weighted average remaining contract term, Options exercisable	9 years 4 months 6 days
Aggregate Intrinsic Value
Aggregate intrinsic value, Options outstanding	$ 3	$ 40
Aggregate intrinsic value, Options vested and expected to vest	0
Aggregate intrinsic value, Options exercisable	$ 3

Stockholders' Equity - Summary of Restricted Stock Unit Activity and Weighted Average Exercise Price (Details) - RSUs - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Number of Shares
Beginning balance outstanding (in shares)	5,064
Awarded (in shares)	3,893
Vested (in shares)	(433)
Forfeited (in shares)	(471)
Non-vested and outstanding at end of period (in shares)	8,053
Expected to vest (in shares)	5,285
Weighted Average Grant Date Fair Value (usd per share)
Beginning balance outstanding (in dollars per share)	$ 12.53
Awarded (in dollars per share)	1.17
Vested (in dollars per share)	16.94
Forfeited (in dollars per share)	16.61
Non-vested and outstanding at end of period (in dollars per share)	6.56
Expected to vest (in dollars per share)	$ 7.02
Aggregate Fair Value
Aggregate fair value, Non-vested and outstanding	$ 7,879	$ 19,193
Aggregate fair value, Expected to vest	$ 5,153

Stockholders' Equity - Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	Mar. 08, 2024	Mar. 31, 2024
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock available for issuance (up to) (in shares)		42,367,744
Options term (in years)		10 years
Unrecognized compensation cost related to novested share-based compensation arrangements		$ 2.8
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1 year 10 months 24 days
Stock Option \| 2019 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)		2,286,084
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock available for issuance (up to) (in shares)		2,000,000
Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)		948,453
Incentive Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock available for issuance (up to) (in shares)		11,459,009
Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)		5,994,216
Increase in number of shares of common stock available for issuance	5,300,000
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1 year 10 months 24 days
Unrecognized compensation cost related to nonvested share-based compensation arrangements		$ 37.7
Restricted stock units \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Restricted stock units \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years

Stockholders' Equity - Schedule of Stock-Based Compensation Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 7,558	$ 11,332
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	343	2,035
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,455	2,404
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1,798	2,632
Product development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,962	$ 4,261

Restructuring - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring expense	$ 3,309	$ 11,515

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Restructuring Reserve [Roll Forward]
Balance, beginning of period	$ 2,076	$ 803
IT contract termination costs	715	5,744
Severance and other compensation associated costs	2,594	16,920
Cash payments	(3,577)	$ (21,391)
Balance, end of period	$ 1,808

Restructuring - Schedule of Restructuring Liability by Cost Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring expense	$ 3,309	$ 11,515
Severance and other compensation associated costs
Restructuring Cost and Reserve [Line Items]
Restructuring expense	2,594	11,514
Lease restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring expense	0	1
Contract Termination
Restructuring Cost and Reserve [Line Items]
Restructuring expense	$ 715	$ 0

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Income Tax Contingency [Line Items]
Provision for income taxes	$ 362	$ 1,214
Valuation allowance			$ 211,200
Increase in valuation allowance recorded as an expense	24,900
Accounting Standards Update 2020-06
Income Tax Contingency [Line Items]
Decrease in valuation allowance charged to equity			23,700
Foreign Tax Authority
Income Tax Contingency [Line Items]
Increase in valuation recorded			$ 23,700
Provision for income taxes	$ 400

Equity Method Investments (Details) - USD ($)		3 Months Ended
Equity Method Investments (Details) - USD ($)	Feb. 13, 2022	Mar. 31, 2023	Mar. 31, 2024	Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]
Equity method investment, contribution, term	5 years
Claire Holdings, Inc.
Schedule of Equity Method Investments [Line Items]
Payments to acquire equity method investments	$ 19,000,000
Ownership percentage	19.20%
Other operating income (expense), net		$ 600,000
Equity Method Investments			$ 0	$ 0
Claire Holdings, Inc. \| Pasaca Capital Inc. (“Pasaca”)
Schedule of Equity Method Investments [Line Items]
Payments to acquire equity method investments	$ 80,000,000
Ownership percentage	80.80%

Variable Interest Entity (Details)	Feb. 28, 2022 corporation
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable interests, number of professional corporations	4

Related Parties (Details) - USD ($) $ in Thousands	3 Months Ended
Related Parties (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Revenue from related parties	$ 85,149	$ 107,661
Accounts receivable, related parties	71,365		$ 81,802
Accounts for doubtful accounts	9,235		9,290	$ 9,239
Related Party
Related Party Transaction [Line Items]
Revenue from related parties	0	$ 3,800
Accounts receivable, related parties	$ 2,100
Accounts for doubtful accounts			$ 1,500

Divestiture - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
Divestiture - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 0	$ 13,819
Restricted cash	1,960	$ 12,197	$ 2,143
Kasamba, Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	16,900
Deferred proceeds from divestiture of business	2,600
Restricted cash			$ 11,800
Maximum length of time, restricted cash held in escrow			15 months
Increase (decrease) of restricted investments			$ 9,800
Disposal Group, Held-for-sale, Not Discontinued Operations \| Kasamba, Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on disposition of business	$ 1,800		$ 17,600

LivePerson (NASDAQ:LPSN)
Historical Stock Chart
From Apr 2024 to May 2024

LivePerson (NASDAQ:LPSN)
Historical Stock Chart
From May 2023 to May 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

LPSN LivePerson Inc

LivePerson Inc News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

LPSN LivePerson Inc

LivePerson Inc News

Your Recent History

Company

Business

Popular

Get The App